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ABSTRACT 
General Electric PETtrace Cyclotron as a Neutron Source  
for Boron Neutron Capture Therapy. (August 2005) 
Andrey Bosko, B.S., Moscow Engineering-Physics Institute; 
M.S., Moscow Engineering-Physics Institute 
Chair of Advisory Committee: Dr. W. Daniel Reece 
This research investigates the use of a PETtrace cyclotron produced by General 
Electric (GE) as a neutron source for boron neutron capture therapy (BNCT). The GE 
PETtrace was chosen for this investigation because this type of cyclotron is popular 
among nuclear pharmacies and clinics in many countries; it is compact and reliable; it 
produces protons with energies high enough to produce neutrons with appropriate energy 
and fluence rate for BNCT and it does not require significant changes in design to 
provide neutrons. In particular, the standard PETtrace 18O target is considered. The 
cyclotron efficiency may be significantly increased if unused neutrons produced during 
radioisotopes production could be utilized for other medical modalities such as BNCT at 
the same time. 
The resulting dose from the radiation emitted from the target is evaluated using 
the Monte Carlo radiation transport code MCNP at several depths in a brain phantom for 
different scattering geometries. Four different moderating materials of various 
thicknesses were considered: light water, carbon, heavy water, and FluentalTM. The 
fluence rate tally was used to calculate photon and neutron dose, by applying fluence 
 
 iv
rate-to-dose conversion factors. 
Fifteen different geometries were considered and a 30-cm thick heavy water 
moderator was chosen as the most suitable for BNCT with the GE PETtrace cyclotron. 
According to the Brookhaven Medical Research Reactor (BMRR) protocol, the 
maximum dose to the normal brain is set to 12.5 RBEGy, which for the conditions of 
using a heavy water moderator, assuming a 60 μA beam current, would be reached with 
a treatment time of 258 min. Results showed that using a PETtrace cyclotron in this 
configuration provides a therapeutic ratio of about 2.4 for depths up to 4 cm inside a 
brain phantom. Further increase of beam current proposed by GE should significantly 
improve the beam quality or the treatment time and allow treating tumors at greater 
depths. 
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CHAPTER I 
INTRODUCTION 
 
Neutron capture therapy (NCT) is a radiation therapy that uses nuclides that have 
a high capture cross-section for thermal neutrons. This capture reaction, followed by 
disintegration, can result in high energy deposition in the vicinity of reaction site. If such 
nuclides are introduced selectively into tumor cells, it is possible to destroy the tumor 
and largely spare the surrounding normal tissue. The principles of this method were 
described in the middle of 1930’s. Shortly after the discovery of the neutron by J. 
Chadwick in 1932 and the description of the 10B(n,α)7Li-reaction by Taylor and 
Goldhaber in 1935, the basic idea to use neutron capture reactions in cancer treatment 
was published by Locher, an biophysicist with the Franklin Institute in 1936. "In 
particular, there exist the possibilities of introducing small quantities of strong neutron 
absorbers into the regions where it is desired to liberate ionization energy (a simple 
illustration would be the injection of a soluble, non-toxic compound of boron, lithium, 
gadolinium, or gold into a superficial cancer, followed by bombardment with slow 
neutrons)." 
A number of nuclides exists that have a large absorption cross-section for 
thermal neutrons and some of these are listed in Table I-1. Most of these nuclides 
interact with thermal neutrons by the (n,γ) reaction. 
 
 
____________________ 
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This type of reaction results in gamma-ray emission and the resulting gammas 
can penetrate tissue easily, depositing their energy not only in the tumor but in healthy 
tissue. Thus, these nuclides are not suitable for NCT. But some nuclides may be of 
interest for NCT, such as 6Li and 235U. One of the limitations in using these nuclides is 
their toxicity. 
 
Table I-1. Nuclide properties. 
Nuclides Interaction Cross-section σth (barns) 
3He (n,p) 5333 
6Li (n,α) 941 
10B (n,α) 3840 
113Cd (n,γ) 20600 
151Eu (n,γ) 9200 
155Gd (n,γ) 61000 
157Gd (n,γ) 255000 
174Hf (n,γ) 530 
199Hg (n,γ) 2200 
235U (n,f) 585 
241Pu (n,f) 1010 
242Am (n,f) 7000 
 
Most experimental work and clinical approaches in NCT have been based on 10B. 
The first experiments using 10B-NCT were performed in 1940 by Kruger and included  
in-vitro tumor treatment with boric acid and irradiation. Other researchers investigated 
the efficiency of NCT in-vivo after injection of boric acid or boron in an oily suspension 
into a mouse sarcoma. Several years later the treatment of brain tumors was proposed 
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based on selective uptake of a boron compound by the tumor. Data suggested that the 
tumor does not have a blood-brain barrier while healthy tissue does. This absence of a 
blood-brain barrier can lead to higher boron concentrations in brain tumors compared to 
that in healthy brain tissues. 
The first clinical trials in the USA, conducted from 1951 to 1961 using 10B, 
failed. Later, it became clear that the major reason for this failure was low 10B 
concentration in the tumor.  
Elastic scattering of neutrons and the 14N(n,p)14C and 1H(n,γ )2H, nuclear 
reactions produce recoil nuclei and γ-rays during exposure to neutrons. Although the 
neutron capture cross-sections for hydrogen and nitrogen are much lower than that for 
10B, hydrogen and nitrogen are present in such high concentrations that their neutron 
capture background contribute significantly to the total absorbed dose. This background 
and low specificity lead to a low therapeutic ratio. 
Despite these early failures, Dr. Hatanaka, a Japanese neurosurgeon who 
received training with Dr. Sweet at Massachusetts General Hospital at Harvard 
University, returned to Japan in 1968 and continued to develop the technique. He used a 
new boron drug BSH (Na210BB12H11SH, sodium borocaptate), that concentrated 
selectively in tumors. Using this drug he performed open-skull irradiation of brain 
tumors using thermal neutron beams (energy < 0.025 eV) to reach the target without 
losing significant amounts of the thermal beam. Several groups worked at different 
reactors using this technique and treated over 200 patients with some encouraging 
results. At the same time, great progress was achieved in synthesis of boron-containing 
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compounds enriched in the B isotope. These compounds, introduced into a patient’s 
blood, produce in tumor cells a B isotope concentration up to 40 mg/g, more than three 
times larger than that in normal tissue cells. This enables selective destruction of 
malignant tumors. The Japanese experience and recent advances in the evaluation of 
tumor-affinitive boron-containing drugs have spurred renewed interest in NCT and now, 
boron neutron capture therapy (BNCT) is under active investigation all over the world. 
10
10
This type of therapy is the most promising for curing certain malignant tumors, 
especially therapy for glioblastoma multiforme and melanoma. Forty to fifty percent of 
primary central nervous system tumors are gliomas. Approximately 50% of these are 
glioblastoma multiforme and 7% are astrocytomas. Glioblastoma multiforme refers to a 
malignant neoplasm with abundant glial pleomorphism, numerous mitotic figures and 
giant cells, vascular hyperplasia, and focal areas of necrosis. Occurring most commonly 
in the fifth through seventh decades, glioblastoma multiforme usually develops in the 
cerebral hemispheres (more often in the frontal lobes than the temporal lobes or basal 
ganglia) but almost never in the cerebellum. It grows as an irregular mass in the white 
matter and infiltrates the surrounding parenchyma by coursing along white matter tracts, 
frequently involving the corpus callosum and crossing the midline to produce the 
characteristic "butterfly" appearance, see Figure I-1. About one out of 20,000 people 
every year is afflicted by glioblastoma multiforme. The disease is always fatal and is 
hard to treat; death usually comes within six months of onset. Surgery and conventional 
radiation therapies may prolong life for as much as a year but do not stop the spread of 
tumors throughout the brain. 
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Figure I-1. Glioblastoma multiforme. 
 
For these tumor types BNCT is perhaps the only option. B-10, when in or near 
tumor cells, disintegrates after capturing a neutron from an epithermal neutron beam. 
During disintegration high energy particles are produced and these particles deposit a 
large amount of energy in relatively short distances, effectively destroying the molecular 
bonds along their paths (see Figure I-2). If any of the paths leads through a cell nucleus, 
the resulting damage to DNA will likely prevent further cell proliferation. As the ranges 
of the α-particle and the 7Li nucleus in tissue are comparable to the size of a typical 
tumor cell, the damage is limited to those cells that accumulate boron. This means that 
BNCT will make it possible to selectively destroy tumor cells if they will have higher 
10B concentration than healthy ones.  
Historically, the best source of neutrons at the energy and fluence rate levels 
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required for BNCT was a nuclear reactor. BNCT research has used the Brookhaven 
Medical Research Reactor (BMRR), the Massachusetts Institute of Technology Reactor 
(MITR), reactors at the National Engineer Laboratory in Idaho, and other facilities. The 
advantage of a reactor is that the neutrons from reactors are relatively cheap discounting 
capital costs. The disadvantages of reactor are that the capital costs are very high and 
reactors are too complicated for an ordinary clinic to operate, so these clinics cannot 
afford to build and maintain a small nuclear reactor to use as a neutron source. 
Another approach to this problem is to use particle accelerators. These machines 
can accelerate protons to the required energies for the reaction and the bombarded target 
emits neutrons at rates and energy levels appropriate for BNCT. These accelerators are 
cheaper, easier to operate, and pose less overall risk than nuclear reactors. Accelerator 
neutron sources are well understood and implemented in a number of research facilities. 
 
Figure I-2. 10B(n,α)7Li reaction. 
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CHAPTER II 
THEORY 
 
II-1. Background 
There are a number of reactor and accelerator-based BNCT facilities around the 
world. The following is the summary of recent studies. 
Argentina 
Several studies were performed by Argentinean scientists in collaboration with 
the Massachusetts Institute of Technology (MIT) Laboratory for Accelerator Beam 
Applications (LABA). One recent work (Burlon et al 2001) investigated the use of the 
13C(d,n)14N reaction as a neutron source for BNCT. This reaction is one of the most 
promising deuteron-induced reactions at low incident energy because of the good 
mechanical and thermal properties of carbon as a target material and carbon has a 
relatively large neutron production cross-section. The 1.5 MeV deuteron beam used in 
these studies was produced by an electrostatic tandem accelerator. This high-current 
accelerator for BNCT was designed for multimilliampere proton or deuteron beams at 
energies of up to 4.1 MeV. A D2O moderator and lead reflector assembly was used to 
provide neutron beam shaping. The dose from the resulting neutron spectrum was 
evaluated at different depths inside a water-filled brain phantom using the dual 
ionization chamber technique for fast neutrons and photons and bare and cadmium-
covered gold foils for the thermal neutron fluence rate. All results were simulated with 
the MCNP code. The experimental dose measurements and calculations evaluated at 1, 
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2, 3, 4, 6, 8, and 10 cm depths on the central axis of the phantom. The treatment time 
was calculated to be 56 minutes at the depth of 5.6 cm assuming a 4 mA deuteron 
current. 
The same authors recently proposed a design for an optimized neutron-beam 
shaping assembly for accelerator-based BNCT (Burlon et al 2004). They proposed a   
Li-metal target based on the 7Li(p,n)7Be reaction to produce neutrons. The bombarding 
proton energies covering the range from 1.92 to 2.5 MeV were used for calculations. A 
proton energy of 2.3 MeV has some advantages because of the relatively high neutron 
yield at this energy, which limits the fast neutron dose to healthy tissue and minimizes 
the treatment times. The beam shaping assembly proposed in this work consists of 
successive stacks of aluminum, polytetrafluoroethylene (Teflon), and LiF as moderators 
and neutron absorbers, and lead as a reflector. Lead was used as reflector material in 
their previous work (Burlon et al 2001) and it was shown to be a better than graphite. 
This assembly is easy to build and relatively inexpensive compared to the widely used 
Fluental moderator. Three moderator thicknesses were considered (18, 26 and 34 cm) 
and a 34 cm moderator gave the best performance. 
Australia 
Australian researchers explored the “near threshold” reaction for the 7Li(p,n)7Be 
reaction for use in BNCT (Zimin et al 2000). The 7Li(p,n)7Be reaction has a proton 
energy threshold of 1.881 MeV and is used in many studies as a source of nearly 
monoenergetic neutrons. The maximum achievable epithermal neutron fluence rate on 
the surface of the phantom was shown to be about 8x107 n/cm2-s/mA in the 1.89 – 1.95 
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MeV proton energy range. Increasing the proton energy in this range has a little benefit 
because the increase in useful neutron fluence rate is relatively small. Thus, the concept 
of near-threshold BNCT is feasible only with very high proton beam currents, on the 
order of 10-20 mA. 
Italy 
Accelerator-based BNCT has also been studied in Italy. One of the researchers 
(Bisceglie et al 2000) investigated the optimal energy of epithermal neutron beams for 
BNCT. The results of the simulations, performed for monoenergetic neutron beams over 
a wide energy range, were analyzed to find the optimal neutron energy for deep-seated 
tumors. Based on these simulations different accelerator-based neutron-production 
reactions and beam-shaping assembly configurations were compared. 
The most recent Italian work (Terlizzi et al 2004) includes a study of Radio 
Frequency Quadrupole (RFQ) accelerators as an epithermal neutron source for BNCT. A 
high intensity RFQ accelerator is under construction in Italy as a part of the TRASCO 
project that includes design of an Accelerator Driven System (ADS) for nuclear waste 
transmutation. This facility will be able, on one hand, to accelerate a 10 mA proton beam 
up to 20 MeV for nuclear studies and, on the other hand, to accelerate a 30 mA proton 
beam up to 5 MeV for BNCT studies. Terlizzi et al 2004 also considered a second 
current regime with proton energies at 2 MeV. Such an accelerator could be used with a 
7Li(p,n)7Be target to produce neutron beams. An appropriate choice of the function 
parameters of the RFQ (modulation, efficiency of acceleration, phase shift, etc…) allows 
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relatively compact accelerators, which could eventually lead to hospital-based BNCT 
facilities. 
Japan 
Japan has made a huge scientific contribution in the study of BNCT. Some 
studies done in Japan in recent years deal with accelerator-based BNCT. Researchers 
(Tanaka et al 2001) investigated the feasibility of neutron capture therapy using an 
accelerator-based neutron source with the 7Li(p,n)7Be reaction produced by 2.5 MeV 
protons. The neutron beam produced by the Hiroshima University radiological research 
accelerator (HIRRAC) and the heavy water neutron irradiation facility in the Kyoto 
University reactor (KUR-HWNIF) were compared with respect to contamination dose 
ratios for fast neutrons and gamma rays. These contamination ratios to the boron dose 
were estimated in a water phantom 20 cm in diameter and 20 cm in length to simulate a 
human head. The 7Li(p,n)7Be neutrons produced by 2.5 MeV protons combined with 20-
, 25- or 30-cm thick D2O moderators 20 cm in diameter produced irradiation fields for 
neutron capture therapy with depth–dose characteristics similar to those from the 
epithermal neutron beam at the KUR-HWNIF. Tanaka et al 2002 also confirmed the 
feasibility of using a near-threshold 7Li(p,n)7Be neutron source for BNCT. 
A recent study (Yonai et al 2003) at the Cyclotron and Radioisotope Center of 
Tonoku University focuses on optimizing the epithermal neutron field with an energy 
spectrum and intensity suitable for BNCT for various combinations of neutron-
producing reactions and moderator materials. A thick Ta target was selected as a neutron 
source, based on the measurement of angular distribution and neutron energy spectra. 
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All calculations were made using the MCNPX code. This target was simulated as 
bombarded by 50 MeV protons in a 300 μA beam current and neutrons emitted at 90 
degrees from the target. A moderating and shaping assembly used in that simulation was 
composed of iron, AlF3, Al, 6LiF and lead. The depth dose distributions in a cylindrical 
phantom showed that, for 1 hour or less of therapeutic time, the best moderator 
assembly, which is 30 cm thick iron, 39 cm thick AlF3-Al-6LiF and 1 cm thick lead, 
provides an epithermal neutron fluence rate of 0.7x109 n/cm2-s. This results in a tumor 
dose of 20.9 RBEGy at a depth of 8 cm in the phantom. 
This simulation was followed by another study (Yonai et al 2004) which was 
done to validate these calculations. The epithermal neutron energy spectrum passing 
through the moderators was measured using a 3He gas spectrometer covered with silicon 
rubber loaded with natural boron and polyethylene moderator. The depth distribution of 
the reaction rates was obtained using gold foils in an acrylic phantom set behind the rear 
surface of the moderators. The measured results were compared with the calculations 
using MCNPX code. Agreement between the calculations and measurement was to 
within 10% for the neutron energy spectra and to within 20% for the depth distribution. 
Russia 
Russian researchers proposed using a proton accelerator complex for fast neutron 
therapy and for neutron-capture therapy in Russia several years ago (Bayanov et al 
1998). This project was based on experience accumulated at the Institute of Physics and 
Power Engineering (IPPE) and the Budker Institute of Nuclear Physics (BINP). The 
Russians developed an electrostatic accelerator tandem without accelerator columns – 
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usually an integral part of accepted accelerator scheme. This specific geometry of 
accelerating electrodes and tandem optics allows maximum reliability in acceleration of 
high-current proton beams in a continuous mode and a reliable gaseous target can be 
used for continuous operation. The main components and technical decisions for tandem 
construction were tested on a 1 MeV prototype which operated in the pulse mode as an 
H-ion source injector in a synchrotron. Wide experience has been accumulated at BINP 
in design of negative ion sources of different types. A high power H-continuous ion 
source with a 40 mA current can be used with lithium neutron-producing target. Liquid 
lithium targets are necessary to operate with this 100 kW proton beam. For vertical 
beams a thin lithium layer on the surface of a tungsten disk cooled by a liquid metal is 
proposed, and a flat liquid lithium jet flowing through the narrow nozzle is proposed for 
a horizontal beam. 
One recent investigation (Kononov et al 2004) performed at IPPE in 
collaboration with Lawrence Berkley National Laboratory and Idaho National 
Engineering and Environmental Laboratory was to optimize moderator size for creating 
epithermal neutron beams for BNCT based on this proton accelerator and the 7Li(p,n)7Be 
reaction as neutron source. Such a neutron source is now under construction on the IPPE 
high current proton accelerator KG-2.5. The best characteristics are obtained using 
magnesium fluorine. Studies suggest that the optimal configuration for the beam shaping 
assembly one made from polytetrafluoroethylene and magnesium fluorine. With such a 
moderator and a 2.3 MeV, 10 mA proton beam, calculations of in-phantom dose 
distributions show that the advantage depth is 9 cm. The advantage depth determines the 
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depth in the phantom for which the tumor just receives more dose than the maximum 
healthy tissue dose (Kudchadker et al 1999). The therapeutic ratio is 6 at 3 cm depth, 
and the advanced dose rate at 9 centimeters is approximately 1 RBEGy per minute, 
which means that maximum treatment time will be about 10 minutes. 
United Kingdom 
Many studies have been done at the University of Birmingham. The Dynamitron 
accelerator at the University of Birmingham has the potential to be the first clinical 
accelerator-based BNCT facility in the world. The accelerator has demonstrated proton 
currents in excess of 1 mA at a potential of 2.8 MV. The proton beam strikes a thick 
natural lithium target positioned at the center of a moderating structure, generating a 
neutron source intensity of 1.37x1012 n/s from the 7Li(p,n)7Be reaction. There were a 
number of studies considering this type of neutron source. A part of this research was 
analysis of the best proton energy and design for an epithermal neutron beam. A review 
of some of these works follows. 
The first paper (Allen et al 1995) described a design concept for an accelerator-
based epithermal neutron beam for BNCT. The proposed design was suited to the 
University of Birmingham’s modified Dynamitron accelerator that can deliver a 5 mA 
vertical proton beam with an energy up to 3 MeV. The facility design concept includes 
several features. One capability is using a 5 mA beam producing an epithermal neutron 
therapy beam with a neutron fluence rate of 5x1012 n/cm2-s with low gamma-ray 
contamination. A thick natural lithium target was used to generate neutrons through the 
7Li(p,n)7Be reaction. Another proposal was to use a 6Li-poisoned heavy water moderator 
 
 14
to produce a therapy beam with the desired energy spectrum. The neutron fluence rate is 
maximized by using a graphite reflector placed around the sides and at the rear of the 
moderator. A hemispherically shaped therapy beam exit surface was designed to 
partially wrap around a patient’s head to maximize the delivery of therapeutic neutrons. 
The design performance described above has been validated by experiment and, while 
promising, it suffers some limitations. The most significant was the difficulty in 
extracting a neutron beam vertically from the Dynamitron accelerator, which has a 
vertical proton beam. Also some restrictions exist on practical patient positioning and 
several safety issues remain regarding positioning the proton beam and lithium target 
directly above a patient. 
Thus, another study was conducted (Allen et al 1999) to explore further design 
options available to produce a horizontal neutron therapy beam using the vertical proton 
beam. A 7Li(n,p)7Be thick natural lithium target was used. This target produces a 
distribution of neutrons peaked in intensity in the direction of the incident proton beam. 
The neutron fluence rate is expected to decrease gradually at angles away from the 
forward direction. Furthermore, the mean energy of the emitted neutrons also decreases 
with increasing angle, so less moderating material could be used. The selected proton 
energy for that study was 2.8 MeV. Finally, the authors concluded that it was 
unnecessary to use a collinear neutron beam; a beam extracted at 90 degrees to the 
direction of the incoming protons produces a better result in terms of lower mean 
neutron energy at the therapy position. This lower energy improves the achievable 
therapeutic ratios within a head phantom; the ratios are higher at all depths for an 
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orthogonal beam delivering the same therapy neutron fluence. The expected treatment 
time with the proposed 5 mA orthogonal Birmingham facility is of the order of 19 - 40 
minutes to deliver a maximum healthy tissue photon equivalent dose of 12.6 RBEGy. 
Other research (Allen et al 2000) considered the best proton energy for 
accelerator-based BNCT using the 7Li(p,n)7Be reaction and the following proton 
energies: 2.15, 2.25, 2.4, 2.8, 3.1 and 3.5 MeV. The neutron yield from a thick natural 
lithium target was calculated as a function of angle and energy at each listed proton 
energy. The calculated neutron yields were used as the source term in a series of neutron 
and coupled neutron-photon Monte Carlo simulations using the general purpose code 
MCNP. This code simulated the transport of neutrons and neutron-generated photons 
through target, moderator, reflector, shield and phantom. The moderator material chosen, 
FluentalTM, consists of aluminum, fluorine and natural lithium. Various thicknesses of 
moderator were studied and the individual dose components were calculated as a 
function of depth in the phantom. The moderator design was optimized using in-
phantom treatment figures of merit, as well as the beam quality. They concluded, that at 
proton energies below 2.8 MeV, there is no observed variation in the achievable therapy 
beam quality; but a price is paid in terms of treatment time by not choosing the upper 
limit of this range. For higher proton energies, the beam quality falls with no 
improvements in treatment time for optimum configuration. 
Another study (Mason et al 2001) using the Birmingham BNCT Facility 
investigated the dependence of the resulting neutron beam on the proton energy and the 
thickness of moderating material. MCNP was used to explore the extent of this 
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dependence and the corresponding dose rates in a water-filled polyethylene phantom. 
The variation in the mean in-phantom neutron energy that can be achieved with an 
accelerator-based neutron source was analyzed. With a 320 mm moderator, the mean 
neutron energy was shown to vary from 4.18 keV at a depth of 20 mm to 0.019 keV at a 
depth of 65 mm for proton energies of 3.5 and 2.15 MeV, respectively. Changing the 
energy of the proton beam produced the greatest variation, while the thickness of 
moderating material seems to have a lesser effect. The mean neutron energy varied most 
at greater depths in the phantom. An irradiation time on the order of several hours was 
needed to deliver the required dose. 
A more recent study at the Birmingham facility was conducted in November 
2003 (Culbertson et al 2004), analyzing the final epithermal beam design for the BNCT 
facility constructed at the University of Birmingham. The final moderator and facility 
design includes a region of Fluental to moderate the neutron spectrum to appropriate 
therapy energies, with a graphite reflector, and a Li-polyethylene sheet to provide a 
delimited neutron beam port. A schematic of the system is shown in Figure II-1. 
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Phantom 
Figure II-1. Current facility design at the University of Birmingham. 
 
The dual ionization chamber technique was used together with foil activation to 
quantify the fast neutron, photon, and thermal neutron beam dose components in a large 
rectangular phantom exposed to the beam with a 12-cm diameter beam delimiter in 
place. The dosimetric characteristics of the Birmingham BNCT facility when measured 
indicated adequate agreement with in-phantom MCNP predictions, within 10% for the 
photon and thermal neutron dose, and within 25% for the proton recoil dose along the 
main beam axis. 
United States 
Many studies have been done in USA, mostly at Lawrence Berkeley Laboratory, 
focused on the accelerator-based neutron sources for BNCT. One proposed approach is 
to use a DC electrostatic quadrupole (ESQ) accelerator to deliver more than 100 mA 
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beam of 2.5 MeV protons onto a lithium target (Anderson et al 1994, Kwan et al 1995). 
Such a high beam current can reduce treatment time to less than an hour and also has an 
additional advantage of allowing the use of refractory lithium target material to 
withstand the intense power load. Beam current of more than 100 mA can only be 
achieved by electrostatic accelerators. But, at present, the critical path lies in the 
development of a compact, high current, multi-megavolt, DC power supply. 
In other research (Bleuel et al 1998) the 7Li(p,n)7Be reaction was again 
investigated as an accelerator-driven neutron source for proton energies between 2.1 and 
2.6 MeV. Epithermal neutron beams shaped by three moderator materials – Al-AlF3, 
7LiF, and D2O, were analyzed and their usefulness for boron neutron capture therapy 
treatments evaluated. The MCNP code was used to simulate radiation transport through 
the moderator. Fluence and dose distributions in a head phantom were calculated using 
BNCT treatment planning software. The treatment time was estimated to be about 40 
minutes for a single beam treatment, using a 20 mA proton beam and a 7LiF moderator. 
The tumor dose deposited at a depth of 8 cm was calculated to be about 21 RBEGy. This 
research was followed by an experimental study (Bleuel et al 1999) at the Lawrence 
Berkeley National Laboratory’s 88-inch cyclotron. The epithermal neutron beams, 
created by using several microamperes of 2.5 MeV protons on a lithium target, were 
characterized. The neutron moderating assembly consisted of Al-AlF3 and Teflon, with a 
lead reflector to produce an epithermal spectrum strongly peaked at 10 – 20 keV. Gold 
foil activation analysis was used to measure the thermal fluence rate in a cubic lucite 
head phantom. Portions of the neutron spectrum were measured by in-air activation of 
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six cadmium-covered materials (Au, Mn, In, Cu, Co, W) with high epithermal neutron 
absorption resonances. The results agreed reasonably with the Monte Carlo 
computational models, confirming their validity. 
 
II-2. Monte Carlo code 
There are several Monte Carlo codes that are used in medical physics 
calculations. In this work a general-purpose Monte Carlo N – Particle (MCNP) code was 
used (Briermeister 2000). This code can be used for neutron, photon, electron, or 
coupled neutron/photon/electron transport. All calculations have been done in two 
transport modes: combined neutron/photon transport, where the photons are produced by 
neutron interactions, and photons only. These transport modes are discussed later. The 
neutron energy regime is from 10-11 MeV to 20 MeV for all nuclides and up to 150 MeV 
for some nuclides, the photon energy regime is from 1 keV to 100 GeV. 
 
II-2-1. Neutron/photon transport 
When simulating a particle collision with a nucleus a series of probabilities and 
simulation choices have to be made. The following discussion describes this sequence. 
 
II-2-1-1. Identification of the collision nuclide 
If there are n different nuclides forming the material in which a collision 
occurred, and if ξ is a random number on the unit interval [0,1), then the kth nuclide is 
chosen as the collision nuclide if 
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where Σti  is the macroscopic total cross-section for nuclide i. 
 
II-2-1-2. Free gas thermal treatment 
Either the S(α,β) thermal scattering treatment, which is a complete representation 
of thermal neutron scattering by molecules and crystalline solids, or the velocity of the 
target nucleus is sampled for low – energy neutrons. This treatment is necessary to 
account for the thermal motion of the atom and/or the presence of other atoms near the 
collision site. MCNP uses a thermal treatment based on the free gas approximation to 
account for the thermal motion. It also has a S(α,β) capability that takes into account the 
effects of chemical binding and crystal structure for reactions with incident neutron 
energies below about 4 eV. The free gas thermal treatment consists of adjusting the 
elastic cross-section and taking into account the velocity of the target nucleus when the 
kinematics of a collision are being calculated. 
 
II-2-1-3. Optional generation of photons 
Photons are generated if the problem is running in the neutron/photon transport 
mode and if the collision nuclide has a nonzero photon production cross-section. Any 
photons generated at neutron collision sites are temporarily stored in the bank. There are 
two different methods to determine photon energies and directions. 
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The first method is the Expanded Photon Production Method. In this method, the 
reaction n responsible for producing the photon is sampled from 
∑∑∑
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where ξ is a random number on the interval (0,1), N is the number of photon production 
reactions, and σi is the photon production cross-section for reaction i at the incident 
neutron energy. Every neutron reaction has associated energy-dependent angular and 
energy distributions for the secondary neutrons. Moreover, every photon reaction has 
associated energy-dependent angular and energy distributions for the secondary photons. 
The second method is the “30x20” Photon Production Method. This method uses 
photon production data contained in older libraries. In contrast to the expended photon 
production data, the only secondary photon data used are a 30x20 matrix of photon 
energies; that is, for each of 30 incident neutron energy groups there are 20 equally 
probable photon energies. 
 
II-2-1-4. Modeling of the neutron capture 
There are two ways of treating capture: analog and implicit.  
In analog capture, the particle is killed with probability σa/σT, where σa and σT 
are the absorption and total cross-sections of the collision nuclide for the incoming 
neutron energy. MCNP defines the absorption cross-section as the sum of all (n,x) cross-
sections, where x is anything except neutrons. For all particles killed by analog capture, 
the entire particle energy and weight are deposited in the collision cell. 
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The default method of neutron capture used by MCNP is the implicit capture. For 
that capture, the neutron weight Wn is reduced to as follows: 'nW
n
T
a
n WW *1
' ⎟⎟⎠
⎞
⎜⎜⎝
⎛ −= σ
σ
     (3) 
For implicit capture, a fraction σa/σT of the incident particle weight and energy is 
deposited in the collision cell corresponding to that portion of the time that the particle is 
captured. 
 
II-2-1-5. Elastic and inelastic scattering 
The selection of an elastic collision is made with probability 
aT
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where  σel is the elastic scattering cross-section. 
 σin is the inelastic cross-section. 
 σa is the absorption cross-section. 
 σT is the total cross-section, σT= σel+ σin+ σa. 
The selection of an inelastic collision is made with probability 
aT
in
σσ
σ
−      (5) 
The type of inelastic reaction, n, which includes any neutron out process – (n,n’), (n,f), 
(n,np), etc., is sampled from 
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where ξ is a random number on the interval [0,1), N is the number of inelastic 
interactions, and the σi’s are the inelastic reaction cross-sections for the incident neutron 
energy. For both elastic and inelastic scattering, the direction of exiting particles usually 
is determined by sampling angular distribution tables from the cross-section files. 
 
II-2-1-6. S(α,β) treatment 
If the neutron energy is low enough and an appropriate S(α,β) table is available, 
the collision is modeled by the S(α,β) treatment instead of by step II-2-1-5, which 
describes elastic and inelastic scattering. During this treatment the zero-temperature 
elastic cross-section is adjusted to account for the thermal motion of the atom. The 
elastic scattering treatment is chosen with probability σel/(σel+σin). The S(α,β) thermal 
scattering treatment also allows the representation of scattering by multiatomic 
molecules. For inelastic scattering, the distribution of secondary energies is represented 
by a set of equally probable final energies for each member of a grid of initial energies 
from an upper limit of typically 4 eV down to 10-5 eV. Also, there is a set of angular 
data, which corresponds to each initial and final energy.  
 
II-2-2. Photon interactions 
Sampling of the collision nuclide, analog capture, implicit capture, and other 
aspects of photon interactions is the same as for neutrons. But the collision physics is 
completely different. There are two photon transport models used by MCNP: simple and 
detailed. 
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The first is the simple treatment method. This method ignores coherent 
(Thomson) scattering and fluorescent photons from photoelectric absorption. It is 
intended for high-energy photon problems or problems where electron binding effects 
may be neglected. 
Usually, the default method for photon transport in MCNP is the detailed physics 
method. This method includes coherent (Thomson) scattering and accounts for 
fluorescent photons after photoelectric absorption. Form factors are used with coherent 
and incoherent scattering to account for electron binding effects. 
 
II-2-3. Tallies 
MCNP provides seven standard neutron tallies, six standard photon tallies, and 
four standard electron tallies. All tallies are normalized to be per starting particle. The F4 
tally which represents the average fluence in a cell has been used in this research. 
Another name for the F4 tally is Track Length Estimate of Cell Fluence rate. The 
definition of particle fluence rate is = )),,( tEr
→Φ ,,( tErN →ν , where ν is a particle velocity, 
N is a particle density or particle weight/unit volume. Roughly speaking, the time 
integrated fluence rate is 
VWTVWt
V
dVdEdttEr lV t E //),,( ==Φ∫ ∫ ∫ → ν     (7) 
where  W is a particle weight. 
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Tl is a track length (cm) = transit time*velocity. 
 V is a volume (cm3). 
More precisely, let ds=νdt. Then the time-integrated fluence rate is 
∫ ∫ ∫∫ ∫ ∫ →→ =Φ ν E sV E t VdVdsdEtErNVdVdtdEtEr ),,(),,(    (8) 
Because ds is a track length density, this integral is estimated by summing 
WT
),,( tErN
→
l/V for all particle tracks in the cell, time range, and energy range. This tally is 
generally quite reliable because there are frequently many tracks in a cell (compared to 
the number of collisions), leading to many contributions to this tally.  
In this research the resulting tallies are multiplied, using FM tally multiplier, by 
the Neutron Fluence Rate-to-Dose Rate Conversion Factors given in Tables II-1         
and II-2. These conversion factors convert the average fluence rate in the cell to the 
biological dose equivalent rate. 
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Table II-1. Neutron fluence rate-to-dose rate conversion factors       
(ICRP-21). 
Energy, MeV DF(E), (rem/hr)/(n/cm2-s) 
2.5E-08 3.85E-06 
1.0E-07 4.17E-06 
1.0E-06 4.55E-06 
1.0E-05 4.35E-06 
1.0E-04 4.17E-06 
1.0E-03 3.70E-06 
1.0E-02 3.57E-06 
1.0E-01 2.08E-05 
5.0E-01 7.14E-05 
1.0 1.18E-04 
2.0 1.43E-04 
5.0 1.47E-04 
10.0 1.47E-04 
20.0 1.54E-04 
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Table II-2. Photon fluence rate-to-dose rate conversion factors         
(ICRP-21). 
Energy, MeV DF(E), (rem/hr)/p/cm2-s) 
0.01 2.78E-06 
0.015 1.11E-06 
0.02 5.88E-07 
0.03 2.56E-07 
0.04 1.56E-07 
0.05 1.20E-07 
0.06 1.11E-07 
0.08 1.20E-07 
0.1 1.47E-07 
0.15 2.38E-07 
0.2 3.45E-07 
0.3 5.56E-07 
0.4 7.69E-07 
0.5 9.09E-07 
0.6 1.14E-06 
0.8 1.47E-06 
1 1.79E-06 
1.5 2.44E-06 
2 3.03E-06 
3 4.00E-06 
4 4.76E-06 
5 5.56E-06 
6 6.25E-06 
8 7.69E-06 
10 9.09E-06 
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II – 3 GE PETtrace cyclotron 
This research investigates the possibility of making BNCT available for clinics 
and research groups that do not have a specially designed BNCT nuclear reactor or an 
accelerator. There are a large number of medical cyclotrons used for medical 
radionuclide production in the nuclear pharmacies and hospitals. These cyclotrons are 
designed mostly for fluorodeoxyglucose (FDG) production. FDG is manufactured in an 
automated synthesis unit from 18F. This nuclide is produced in a cyclotron by proton 
bombardment of enriched water (18O).  
In this research the General Electric (GE) PETtrace cyclotron normally used to 
produce FDG is examined for use in BNCT (Figure II-2).  
The GE PETtrace was chosen for this investigation because this type of cyclotron 
is popular among nuclear pharmacies and clinics in many countries (about 75 PETtraces 
have been sold world wide); it’s compact and reliable; it produces protons with energies 
large enough to produce neutrons with appropriate energy and fluence rate for BNCT 
and it does not require significant changes in design to provide neutrons suitable for 
BNCT. The energy of protons made in this cyclotron is fixed at 16.5 MeV. The current 
on the target runs up to 60 μA. Targets are accessible, easily changeable, and this 
cyclotron can use dual targets simultaneously, so it gives flexibility to work on 
radionuclide production and BNCT with minimal investment of time and workforce. 
Following is the overview of some design features of the GE PETtrace cyclotron. 
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Figure II-2. The accelerator (adapted from the PETtrace Reference Manual 
(GE Medical Systems 2000)).1 – Magnet System; 2 – Radio-Frequency 
(RF) System; 3 – Ion Source System; 4 – Beam Extraction System; 5 – 
Beam Diagnostic System; 6 – Vacuum System; 7 – Target System; 8 – 
Radiation Shield (option); 9 – Secondary Water Cooling System; 10 – 
Power Distribution System;  11 – Accelerator Control Unit; 12 – 
Electronics and Power Supplies 
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The cyclotron consists of a large cylindrical chamber, placed between the poles 
of a large electromagnet (GE Medical Systems 2000). The cyclotron is used for 
accelerating charged particles (hydrogen ions H- or deuterium ions D- ions). In this 
research, the ability of the cyclotron to accelerate hydrogen ions is used. The chamber is 
evacuated until a very high vacuum exists and H- ions are fed into the center of the 
chamber by means of an ion source. The chamber contains two hollow, D-shaped 
electrodes, called dees, which are connected to a source of very high voltage, oscillating 
with high frequency. When the cyclotron is in operation, the electric charge on these 
dees is reversed very rapidly following the high frequency input voltage. The 
electromagnetic field in conjunction with the high voltage alternating potential causes 
the H- ions inside to take a spiral course. They move faster and faster and acquire more 
and more energy. The H- ions are transformed to protons after reaching the outer rim of 
the chamber and then deflected toward a target. The PETtrace has up to six targets 
mounted on a flange at the front of the cyclotron (Figure II-3). 
Modifying this cyclotron for BNCT presents a number of difficulties:  
-there is no known target for BNCT, so this will require research for a new target 
system; 
-positioning of some cyclotron equipment (behind the targets) will scatter 
neutrons emitted in the forward direction and could result in less fluence rate than 
required by BNCT, so the system configuration might have to be changed; 
-some of these cyclotrons are assembled as self-shielded units (stainless tanks 
filled with borated water surround the cyclotron), and this configuration makes it 
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impossible for them to serve as a neutron source. 
 
 
Figure II-3. Target system, standard configuration (adapted from the 
PETtrace Reference Manual (GE Medical Systems 2000)). 
 
Considering these advantages and disadvantages of GE PETtrace, calculations 
were conducted to study the possibility of using an 18O target as a source of neutrons 
with further reflection, moderation, absorption, and collimation to produce appropriate 
energy and fluence rate for BNCT. 
The 18O target was studied because about 90-95% of time these cyclotrons use 
this target already for FDG production. The efficiency of cyclotron use may be 
significantly increased if unused neutrons produced during FDG production could be 
utilized for other medical modalities such as BNCT at the same time. This research 
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investigates this source using Monte Carlo techniques and standard neutron data files 
subject to the following assumptions: 
-standard running conditions (60 μA target current, 16.5 MeV protons, standard 
18O target); 
-no target filler system behind the target; 
-cyclotron is in a vault with no self-shielding (Figure II-4). 
 
 
Figure II-4. Cyclotron vault with channel for filters and collimators 
proposed for BNCT (side view). 
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CHAPTER III 
MONTE CARLO SIMULATIONS 
 
III – I. Geometry 
Transport of neutrons was simulated using MCNP. For the initial calculation the 
geometry shown in Figure III-1 was used.  
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Figure III–1. Geometry defined as input for the MCNP. 
 
III – 1 – 1. Moderator 
This geometry includes a moderator assembly surrounded by a thick carbon 
reflector. The moderator assembly consists of an aluminum container filled with a 
moderating material. Several different types of materials were investigated to moderate 
neutrons to the epithermal energies: light water, carbon, heavy water. Another popular 
type of BNCT moderator – FluentalTM (43.2% Al, 55.9% F and 0.9% Li by weight), 
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consisting of aluminum, fluorine and natural lithium was also considered (Auterinen et 
al 1993). 
It is worth briefly examining the neutron cross sections of different moderating 
materials. The data were taken from the ENDFB 6.8 cross-section library. As shown in 
Figures III-2 and III-3, all elements have scattering cross-sections of the same order of 
magnitude for neutrons having energies between 1 to 10 MeV. Light hydrogen has the 
highest elastic scattering cross section compared to other elements for neutrons with 
energy less than 1 MeV. On the other hand, it has large absorption cross-section, 
especially for low energy neutrons. The magnitude of carbon, fluorine and deuterium 
scattering cross-sections is about the same; but the absorption cross-section of deuterium 
is much lower compared to that of carbon and fluorine. One of the major components of 
FluentalTM – aluminum, has the lowest scattering and highest absorption cross-sections 
among the other elements. One of the benefits of using FluentalTM as a moderator is that 
the fluorine and aluminum scattering cross-sections have series of resonances at high 
energies which provide a good moderation of neutrons down to epithermal energies, 
where the cross-section is much smaller. A disadvantage of these FluentalTM 
components, compared to other moderating materials, is that both of them, especially 
aluminum, are readily activated by neutrons followed by emission of high-energy 
gammas. 
All moderating materials can be compared using a figure of merit called the 
moderation ratio that depends on three quantities: 
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1. Σs, the scattering cross section for neutrons. Larger is better, because it means 
that the nuclide is efficient at colliding with neutrons. 
2. ξ, the “lethargy decrement”. This is the average energy lost by a neutron in a 
collision with the nuclide. Larger is better, because it means that the neutron is 
thermalized in fewer collisions. 
3. Σa, the absorption cross section for neutrons. Smaller is better, because it means 
that the nuclide is poor at absorbing neutrons. 
Moderating ratio 
a
s
Σ
Σξ
 is a measure of the efficiency of moderation without absorption. 
 
H 
D Al
FC 
Figure III-2. Elastic cross-sections of moderating materials. 
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Heavy water is the best moderator, as it has the highest moderating ratio. But 
other materials were also considered for several reasons. Light water, for example, 
readily absorbs neutrons but, on the other hand, neutrons can be thermalized with a 
moderator of much less thickness. This enables positioning of a phantom closer to a 
neutron source and might compensate the loss of neutrons due to absorption. Using 
FluentalTM may be beneficial, considering moderation of neutrons with high energies. 
 
D 
H
F 
C
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Figure III-3. Absorption cross-sections of moderating materials. 
 
Various thicknesses of moderating material were used in this study, see         
Table III-1. 
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Table III-1. Moderator thicknesses used for the MCNP calculations. 
 25 cm 30 cm 40 cm 50 cm 
H2O Y Y n/a n/a 
D2O Y Y Y Y 
Carbon n/a Y Y n/a 
FluentalTM n/a Y Y n/a 
 
The thickness that provided the lowest fast-neutron contribution to the total 
fluence rate in comparison to the low-energy component and that allowed delivery of the 
necessary dose in a reasonable time was investigated, see Chapter III - 4. 
 
III – 1 – 2. Filter 
Different filters can be used to improve the neutron fluence rate properties. The 
60Ni isotope, for example, can be very useful as a neutron filter to improve the 
epithermal to fast neutron ratio in the BNCT neutron beam (Gritzay et al 2004). In this 
research, a 2-cm thick natural nickel filter was analyzed at different positions inside the 
moderator container. Natural nickel was chosen instead of the pure 60Ni isotope because 
of the high cost of enrichment. The natural abundance of 60Ni is 26.22% and the other 
major isotope of nickel is 58Ni, with a natural abundance of 68.08%. Figures III-4 and 
III-5 show the scattering and the absorption cross-sections for the two nickel isotopes 
compared with the deuterium cross-sections. 
The nickel absorption cross-section is higher than that of heavy water. Thus, the 
Ni filter should slightly decrease the epithermal neutron fluence rate due to absorption. 
However, considering the scattering cross-section, it may be that epithermal fluence rate 
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is increased in the region of 1 – 10 keV. The scattering cross-section of 60Ni has the 
interference minimum at 5 keV with a width of about 7 keV, reaching 0.0001 b at its 
minimum, but cross-section in the energy range of 10 – 100 keV increases up to 200 b. 
Thus, the use of a Ni filter should allow scattering of the high-energy neutrons 
and accumulating of these neutrons in the energy range of 1 – 10 keV. 
 
58Ni 
60Ni D 
Figure III-4. Scattering cross-sections of filter materials. 
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58Ni 
60Ni 
D 
Figure III-5. Absorption cross-sections of filter materials. 
 
III – 1 – 3. Reflector 
The proposed reflector consists of two major parts: a side-reflector and a back-
reflector. Three materials were considered as possible reflectors: graphite, lead, and 
aluminum oxide, Al2O3. After detailed analysis, graphite was chosen as the reflector 
material. The reasons for this decision are the following. Aluminum oxide generates 
many more high-energy photons than graphite and lead when bombarded by neutrons, 
leading to higher photon dose to a healthy tissue. Lead has a lower moderating power 
than graphite, therefore, more fast neutrons are reflected from the lead than from the 
graphite reflector. By itself and by photon induction in the tissues, this higher fast 
neutron component in the neutron beam provides an additional dose to a healthy tissue. 
After choosing graphite as the reflector material, the benefits of using a back-reflector 
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were considered. Scoping calculations using MCNP were carried out for two geometries 
with and without a 22-cm thick graphite back-reflector. The neutron spectra at 3 cm 
depth inside a phantom were compared for both geometries, see Figure III-6. A back-
reflector almost doubled thermal neutron fluence rate at the 3-cm depth. These 
calculations assumed a 30-cm thick side-reflector and a 22-cm thick back-reflector. 
Several studies (Allen et al 1995, Allen et al 2000 and Bleuel et al 1998) considered 
graphite as a reflector. It has been shown that the graphite thickness should be on the 
order of 20 – 30 cm to effectively reflect neutrons and there is a little merit in further 
increasing the graphite thickness. Thus, a 30-cm thick side-reflector and a 22-cm thick 
back-reflector were used for all further analysis. 
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Figure III-6. Neutron spectra for two different geometries. 
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III – 1 – 4. Phantom 
The neutrons emitted from the target slow down through scattering reactions. 
The neutrons leave the moderator and may then interact within the brain for BNCT 
treatment. The phantom brain used to model these interactions consists of an ellipsoid 
with major axies (Harling et al 1995) of 13.6, 19.6 and 16.6 cm to represent human head. 
This phantom was filled with a special composition to simulate brain tissue (ICRU-44 
1989) see Table III-2. The tissue density inside the phantom brain was set to 1.04 g/cm3 
(ICRU-44 1989). The skull bone was considered part of the brain phantom and was not 
defined separately. Bone has approximately the same composition as brain tissue 
(ICRU-44 1989). It contains approximately half the hydrogen and oxygen weight 
fractions, but has a higher density of 1.92 g/cm3 compared to brain tissue, so, basically, 
it cancels this difference out. Also, bone contains a bit of calcium that is not present in 
brain, but this element should not affect very much on moderating properties. 
The tally cells were 0.5 cm diameter spheres at depths of 1, 2, 3, 4, 5, 6, 7 and     
8 cm inside the phantom brain. The fluence rate tally was used in this study to calculate 
photon and neutron dose, by applying fluence rate-to-dose conversion factors given in 
Tables II-1 and II-2. 
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Table III-2. Bone and brain tissue compositions. 
Fraction by weight 
Element 
Bone Brain tissue 
Hydrogen 0.034 0.107 
Carbon 0.155 0.145 
Nitrogen 0.042 0.022 
Oxygen 0.435 0.712 
Sodium 0.001 0.002 
Magnesium 0.002 - 
Phosphorus 0.103 0.004 
Sulfur 0.002 0.002 
Chlorine - 0.003 
Potassium - 0.003 
Calcium 0.225 - 
 
III – 1 – 5. Construction and shielding materials 
Construction and shielding materials used in a given geometry include steel 
walls, a lead shield, container filled with a moderating material, and a lead collimator. A 
steel wall represents the body of a cyclotron and provides additional neutron back-
scattering. A lead block, which is placed next to the target, thickness of 4 cm, is used to 
reduce the dose from the photons emitted from the target. A lead collimator forms the 
neutron beam, thus decreasing unwanted irradiation of healthy tissue. The container wall 
that holds the moderating material consists of aluminum with a thickness of 1 cm for 
structural considerations. 
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III – 2. Source 
The typical 18O target consists of 18O-enriched water kept under a helium 
overpressure in a silver container. The enrichment of 18O in the target is not less than 
95%. When bombarded with neutrons the following reaction occurs in the target: 
MeVnFpO 57.210
18
9
1
1
18
8 −+→+  
18F and neutron production in target is well established. The cross-section for this 
reaction is shown on Figure III-7. 
The neutron spectrum and the angular distribution of neutrons have been 
provided by General Electric (Lundgren and Ingemannson, 2001) and are shown in 
Figures III-8 and III-9. The total neutron yield from the target is 3.21x1011 n/s. As it can 
be seen from the spectrum, most of the neutrons have energy on the order of a few MeV. 
There are several reasons for such a neutron energy distribution.  
1. The target is thick for 16.5 MeV protons (the range of 16.5 MeV protons in water 
is approximately 3 mm). Thus, incident protons are slowing down very fast by 
scattering reactions. Scattering in water produces additional scattered protons 
which have much lower energy (half on average) compared to that of incident 
protons.  
2. The (n,p) reaction cross-section for 18O has a maximum for neutrons in the 
energy range of 3 to 6 MeV. Thus, taking into account the large number of 
scattered protons in that energy range and the negative Q-value of the reaction, 
which is equal -2.57 MeV, a large number of 1 to 2 MeV neutrons may be 
predicted. 
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Figure III-7. Cross-sections for the 18O(p,n)18F reaction (IAEA 2001). 
 
1.1E+11 1.0E+11
5.9E+10
2.9E+10
1.4E+10
6.4E+09
2.9E+09
1.2E+09
5.1E+08
2.1E+08
1.1E+08
1.0E+07
1.
1.
1.
n/
s
0E+08
0E+09
0E+10
1.0E+11
1.0E+12
0 - 1 1 - 2 2 - 3 3 - 4 4 - 5 5 - 6 6 - 7 7 - 8 8 - 9 9 - 10 > 10
Energy, MeV
N
eu
tr
on
Em
is
si
on
R
at
e,
n/
s
 
Figure III-8. Neutron spectrum from H218O target. 
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This data, along with corresponding neutron yield for different angular 
directions, were used to define the neutron source in the MCNP calculations. An 
angular distribution from 0º to 180º with bins covering every 20º was constructed 
for input. 
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Figure III-9. Neutron angular distribution. 
 
Besides neutrons the target also emits gammas. The gamma spectrum was 
provided by General Electric (Lundgren and Ingemannson, 2001) and is shown 
in Figure III-10. Most of the gammas have energy of few MeV and must be 
shielded to prevent additional damage to healthy tissue.  
 
 46
8.8E+11 7.4E+11
2.6E+11
1.6E+11
8.7E+10
4.6E+10
2.2E+10
8.8E+09
2.0E+09
1.9E+08
3.1E+08
1.0E+07
1.0E+08
1.0E+09
1.0E+10
1.0E+11
1.0E+12
1.0E+13
0 - 1 1 - 2 2 - 3 3 - 4 4 - 5 5 - 6 6 - 7 7 - 8 8 - 10 10-12 >12
Energy, MeV
γ/s
 
Figure III-10. Gamma spectrum from H218O target. 
 
The half-value layer of lead, X, for 2 MeV neutrons may be calculated using the 
following formula: 
ρμ ∗−=
)5.0ln(X , cm     (9) 
where μ – is the mass attenuation coefficient of lead for 2 MeV photons (4.6x10-2cm2/g); 
and ρ – is the density of lead (11.35 g/cm3). 
The half-value layer of lead obtained using formula (9) is equal 1.3 cm, so 4 cm 
of lead shield placed in front of the target should reduce the dose from gammas by 
approximately a factor of 8. 
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The gamma source was assumed to be isotropic. This assumption, along with the 
gamma spectrum, was used to specify the gamma source for the MCNP calculations. 
 
III – 3. Input files for MCNP 
Two different input files were created for each moderator thickness. The first 
type contains the anisotropic neutron source with parameters described in III – 2 and 
starts the neutron transport calculation for a given geometry. An example of the input 
file for the neutron dose calculation may be found in APPENDIX A. The other type of 
input file describes an isotropic gamma source with the spectrum shown on Figure III-10 
and initiates a gamma-dose calculation. The input file, shown in the APPENDIX B, 
gives a gamma-dose calculation at different depths inside the brain phantom. Such input 
files were used for each of the proposed moderators and different thicknesses. The 
calculation time for the each geometry was at least one week in order to lower the 
statistical error of the results. 
 
III – 4. Calculations 
Most neutrons have been thermalized at the tally depths. So, in order to know the 
total dose delivered in the tumor and the healthy tissue, other components of the total 
dose were calculated. There are two principal capture reactions for thermal neutrons in 
tissue – 1H(n,γ)2H and 14N(n,p)14C (Turner 1995). The first capture reaction releases a 
2.22 MeV gamma ray, that deposits a fraction of its energy before escaping the phantom. 
In contrast, the nitrogen capture reaction releases 0.626 MeV, which is deposited by the 
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proton and recoil carbon nucleus in the immediate vicinity of the capture site. The 
resulting dose rate from exposure to thermal neutrons was calculated using the following 
formula (10): 
N
N
nthN fFD 14
14
14 Φ=      (10) 
where D14N is the dose rate due to capture in nitrogen (cGy/s), Фth is the neutron fluence 
rate(n/cm2-s), =0.785x10NnF
14 -9 cGy-cm2/n is the kerma factor for thermal neutrons, and 
f14N=0.022 is the weight fraction of nitrogen in brain tissue (Harling et al 1995). Kerma 
factors for this reaction were taken from the literature (Caswell et al 1980). In the 
neutron reaction, 10B(n,γ)7Li, the charged particles are produced with a total kinetic 
energy of 2.34 MeV on average and with a range in tissue of about 10 μm, the order of 
the size of a tumor cell. As a result, the cell containing 10B can be effectively destroyed. 
A similar formula (11) was used to obtain the dose rate from the neutron reaction with 
10B. 
B
nthB FD
10
10 Φ=      (11) 
where D10B is the dose rate due to capture on boron (cGy/s), Фth is the neutron fluence 
rate (n/cm2-s), =8.6x10BnF
10 -12 cGy-cm2/n is the corrected kerma factor for thermal 
neutrons obtained per 1 ppm concentration of 10B in tissue (Rogus et al 1994). The total 
dose to healthy tissue and to tumor cells was calculated using the following formula: 
BBNNphotonfasttissue RBEDRBEDRBEDRBEDRBED 10101414)()()( +++=  (12) 
where D(RBE)tissue is the effective dose rate to tissue (RBEcGy/min), D(RBE)fast is the 
simulated neutron dose rate (RBEcGy/min), D(RBE)photon is the simulated photon dose 
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rate (RBEcGy/min), D14N and D10B are the dose from interactions of thermal neutrons 
with nitrogen and boron, and RBE14N=3.2, RBE10B=1.3 (for normal tissue) and 
RBE10B=3.8 (for tumor) are the relative biological effectiveness given in literature 
(Coderre et al 1993). B-10 concentrations in normal tissue of 11.4 ppm and within the 
tumor of 40 ppm were assumed (Coderre et al 1998). 
All the formulae (10 – 12), along with data obtained from the MCNP 
calculations, were used to evaluate the dose rate for a number of geometries described 
above in Table III-1. 
 
III – 4 – 1. Results for a light water moderator 
Two different thicknesses of light water moderator, 25 and 30 cm, were 
investigated. As predicted, light water heavily absorbed neutrons. Thus, the resulting 
neutron fluence rates came out to be very low, see Figure III-11. The desired neutron 
fluence rate should be on the order of 108 – 109 n/cm2-s to provide a reasonable 
treatment time. 
Figure III-12 shows neutron spectra for both moderator thicknesses at 3-cm depth 
inside the brain phantom. Calculation results for each dose component, using formulae 
(2 – 4), are presented in Tables III-3 and III-4. The fast-to-thermal neutron ratio is about 
the same for both geometries, providing approximately the same therapeutic ratios, i.e. 
ratio of the tumor dose to that of healthy tissue, for different moderator thicknesses. 
Since the neutron fluence rate is very low, the boron capture provides only a little 
contribution to the total dose. Thus, the therapeutic ratio, which is mainly dependent on 
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the dose component coming from the neutron capture in boron, is close to 1. That means 
a light water moderator is not beneficial and cannot be a part of the irradiation system 
used for BNCT.  
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Figure III-11. Neutron fluence rates for two light water moderator 
thicknesses. 
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Figure III-12. Neutron spectra for two light water moderator thicknesses 
at a depth of 3 cm inside a brain phantom. 
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Table III-3. Different dose components for a 25 cm light water moderator. 
Depth, cm Dose components, cGy/min 
1 2 3 4 5 6 7 8 
D(RBE)fast 2.128 2.296 2.232 1.325 1.214 1.082 0.649 0.793 
Error 0.428 0.431 0.419 0.299 0.298 0.285 0.209 0.226 
D(RBE)photon 1.256 1.051 0.942 0.864 0.775 0.706 0.629 0.545 
Error 0.047 0.043 0.040 0.039 0.036 0.035 0.032 0.029 
D(RBE)14N 0.034 0.028 0.026 0.024 0.019 0.014 0.012 0.012 
Error 0.005 0.005 0.005 0.004 0.004 0.004 0.003 0.003 
D(RBE)10B in tumor 0.815 0.672 0.610 0.557 0.443 0.335 0.293 0.273 
Error 0.149 0.136 0.127 0.124 0.114 0.099 0.098 0.094 
D(RBE)10B in healthy tissue 0.079 0.066 0.059 0.054 0.043 0.033 0.029 0.027 
Error 0.005 0.005 0.004 0.004 0.004 0.003 0.003 0.003 
D(RBE) in healthy tissue 3.498 3.441 3.260 2.267 2.051 1.835 1.319 1.376 
Error 0.430 0.433 0.421 0.301 0.300 0.287 0.211 0.228 
D(RBE) in tumor 4.234 4.047 3.810 2.770 2.451 2.138 1.583 1.622 
Error 0.455 0.454 0.440 0.326 0.321 0.304 0.233 0.246 
Therapeutic Ratio 1.21 1.18 1.17 1.22 1.20 1.16 1.20 1.18 
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Table III-4. Different dose components for a 30 cm light water moderator. 
Depth, cm Dose components, cGy/min 
1 2 3 4 5 6 7 8 
D(RBE)fast 0.946 0.987 0.944 0.676 0.410 0.453 0.732 0.324 
Error 0.247 0.231 0.246 0.195 0.162 0.186 0.233 0.153 
D(RBE)photon 0.763 0.657 0.607 0.574 0.547 0.462 0.441 0.387 
Error 0.033 0.030 0.029 0.029 0.029 0.024 0.026 0.023 
D(RBE)14N 0.014 0.013 0.011 0.009 0.008 0.008 0.007 0.006 
Error 0.003 0.003 0.003 0.003 0.002 0.002 0.002 0.002 
D(RBE)10B in tumor 0.327 0.312 0.262 0.216 0.196 0.192 0.162 0.139 
Error 0.087 0.087 0.077 0.073 0.065 0.070 0.070 0.060 
D(RBE)10B in healthy tissue 0.032 0.030 0.026 0.021 0.019 0.019 0.016 0.014 
Error 0.003 0.003 0.003 0.002 0.002 0.002 0.002 0.002 
D(RBE) in healthy tissue 1.754 1.688 1.588 1.280 0.984 0.942 1.196 0.731 
Error 0.250 0.233 0.248 0.197 0.165 0.187 0.235 0.155 
D(RBE) in tumor 2.050 1.970 1.824 1.475 1.161 1.115 1.342 0.856 
Error 0.264 0.248 0.260 0.210 0.177 0.200 0.245 0.166 
Therapeutic Ratio 1.17 1.17 1.15 1.15 1.18 1.18 1.12 1.17 
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III – 4 – 2. Results for a carbon moderator 
Two different thicknesses of a carbon moderator were considered. The moderator 
thickness should be larger compared to a light water moderator. Thus, the first 
calculation was done for a moderator thickness of 30 cm, and the second calculation was 
done for 40 cm of carbon. The neutron fluence rates for two different carbon moderator 
thicknesses are shown on Figure III-13. It can be noted, that again, as it was with a light 
water moderator, the resulting fluence rates are not high enough to provide a reasonable 
treatment time. 
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Figure III-13. Neutron fluence rates for two different carbon moderator 
thicknesses at a depth of 3 cm inside a brain phantom. 
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A 30-cm thick carbon moderator provides a relatively high fluence rate compared 
to a light water moderator and it could be considered as a moderation material. The only 
problem, and it is clearly shown in Figure III-14, is that a 30-cm carbon thickness does 
not provide a sufficient moderating of neutrons, so the resulting fluence rate has a large 
fast neutrons component. 
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Figure III-14. Neutron spectra for two different carbon moderator 
thicknesses at a depth of 3 cm inside a brain phantom. 
 
As a result, the therapeutic ratio for a 30 cm carbon moderator is less than 2 and 
is much lower than that for a 40 cm moderator. The contribution to the total dose in 
healthy tissue due to fast neutron irradiation ranges from 66 to 75 percent for different 
depths inside a brain phantom when a 30-cm carbon moderator is used. But using a 40-
cm moderator, fast neutrons contribute only from 28 to 59 percent to the total dose in 
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healthy tissue. Thus, the therapeutic ratio is much higher for a thicker moderator. 
However, the thicker moderator means a larger distance between the neutron source and 
the target tumor and, as a result, a low neutron fluence rate. So, it was concluded that a 
carbon moderator is not suitable for BNCT use, at least for the irradiation geometry 
considered in this particular research. Different dose components for a carbon moderator 
of 30 and 40 cm thick are shown in Tables III-5 and III-6. 
 
Table III-5. Different dose components for a 30 cm carbon moderator. 
Depth, cm Dose components, cGy/min 
1 2 3 4 5 6 7 8 
D(RBE)fast 3.760 2.537 2.584 2.024 1.776 1.706 1.134 0.889 
Error 0.394 0.324 0.359 0.320 0.319 0.303 0.272 0.218 
D(RBE)photon 0.616 0.523 0.558 0.522 0.460 0.403 0.318 0.302 
Error 0.037 0.032 0.033 0.031 0.030 0.029 0.024 0.024 
D(RBE)14N 0.201 0.174 0.148 0.122 0.099 0.082 0.061 0.046 
Error 0.014 0.013 0.012 0.010 0.009 0.008 0.007 0.006 
D(RBE)10B in tumor 4.757 4.126 3.491 2.894 2.343 1.933 1.443 1.093 
Error 0.398 0.364 0.324 0.293 0.256 0.237 0.196 0.169 
D(RBE)10B in healthy tissue 0.464 0.402 0.340 0.282 0.228 0.189 0.141 0.107 
Error 0.013 0.012 0.011 0.010 0.009 0.008 0.007 0.006 
D(RBE) in healthy tissue 5.041 3.636 3.630 2.951 2.564 2.379 1.653 1.344 
Error 0.396 0.326 0.360 0.322 0.321 0.305 0.274 0.219 
D(RBE) in tumor 9.334 7.359 6.780 5.563 4.679 4.124 2.955 2.331 
Error 0.561 0.488 0.484 0.435 0.410 0.386 0.337 0.277 
Therapeutic Ratio 1.85 2.02 1.87 1.89 1.82 1.73 1.79 1.73 
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Table III-6. Different dose components for a 40 cm carbon moderator. 
Depth, cm Dose components, cGy/min 
1 2 3 4 5 6 7 8 
D(RBE)fast 0.995 1.128 0.564 0.328 0.246 0.230 0.133 0.104 
Error 0.237 0.267 0.171 0.111 0.110 0.095 0.088 0.066 
D(RBE)photon 0.320 0.331 0.293 0.294 0.261 0.222 0.215 0.195 
Error 0.030 0.029 0.028 0.028 0.029 0.025 0.026 0.023 
D(RBE)14N 0.112 0.088 0.078 0.057 0.045 0.035 0.028 0.023 
Error 0.012 0.010 0.009 0.008 0.007 0.006 0.005 0.004 
D(RBE)10B in tumor 2.660 2.089 1.842 1.339 1.064 0.831 0.656 0.533 
Error 0.329 0.282 0.262 0.218 0.187 0.165 0.142 0.124 
D(RBE)10B in healthy tissue 0.259 0.204 0.180 0.131 0.104 0.081 0.064 0.052 
Error 0.011 0.009 0.009 0.007 0.006 0.005 0.005 0.004 
D(RBE) in healthy tissue 1.687 1.750 1.114 0.809 0.656 0.569 0.439 0.373 
Error 0.240 0.269 0.173 0.115 0.114 0.099 0.092 0.070 
D(RBE) in tumor 4.088 3.636 2.777 2.017 1.616 1.319 1.031 0.854 
Error 0.407 0.390 0.314 0.247 0.219 0.192 0.169 0.142 
Therapeutic Ratio 2.42 2.08 2.49 2.49 2.47 2.32 2.35 2.29 
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III – 4 – 3. Results for a FluentalTM moderator 
Another popular BNCT moderator, called FluentalTM, was considered. This 
moderator has several advantages compared to other moderators which were described 
in Chapter III-1-1. Figure III-15 shows neutron fluence rates for a FluentalTM moderator 
with thicknesses of 30 and 40 cm. 
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Figure III-15.Neutron fluence rates for two different FluentalTM moderator 
thicknesses at a depth of 3 cm inside a brain phantom. 
 
The fluence rates obtained were much higher compared to those of carbon. For 
example, the use of FluentalTM instead of carbon provides a factor of 1.5 – 2 increase in 
the total fluence rate. But on the other hand, since the FluentalTM moderator consists of 
elements heavier than carbon, this material has lower moderation ability. Thus, the 
 
 59
neutron spectrum, shown in Figure III-16, has a huge tail because of high energy 
neutrons which haven’t been thermalized enough. This results in a huge contribution to 
the total dose in healthy tissue due to fast neutrons.  
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Figure III-16.Neutron spectra for two different FluentalTM moderator 
thicknesses at a depth of 3 cm inside a brain phantom. 
 
All the dose components along with the therapeutic ratios for different FluentalTM 
moderator thicknesses are summarized in Table III-7 and III-8. Even though the dose 
from of fast neutrons contributes up to 87% to the total dose in healthy tissue; the 
therapeutic ratio is about the same as for a carbon moderator. This is mainly because of a 
higher thermal fluence rate results in a higher dose to a tumor due to the capture reaction 
in boron. Thus, it was concluded that FluentalTM is more attractive as a moderating 
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material than carbon, since it provides the same therapeutic ratios with a higher fluence 
rate of thermal neutrons, which eventually decreases the treatment time. 
 
Table III-7. Different dose components for a 30 cm FluentalTM moderator. 
Depth, cm Dose components, cGy/min 
1 2 3 4 5 6 7 8 
D(RBE)fast 10.65 6.91 5.01 4.44 2.54 2.10 1.62 1.66 
Error 0.784 0.616 0.531 0.505 0.375 0.332 0.305 0.318 
D(RBE)photon 0.786 0.775 0.825 0.798 0.819 0.645 0.549 0.511 
Error 0.043 0.044 0.044 0.044 0.044 0.039 0.036 0.036 
D(RBE)14N 0.254 0.255 0.230 0.209 0.180 0.144 0.114 0.089 
Error 0.017 0.017 0.016 0.015 0.014 0.012 0.011 0.009 
D(RBE)10B in tumor 6.01 6.02 5.45 4.94 4.25 3.40 2.71 2.10 
Error 0.479 0.474 0.445 0.426 0.384 0.341 0.300 0.266 
D(RBE)10B in healthy tissue 0.586 0.587 0.531 0.482 0.414 0.332 0.264 0.205 
Error 0.016 0.016 0.015 0.014 0.013 0.011 0.010 0.009 
D(RBE) in healthy tissue 12.28 8.52 6.59 5.93 3.95 3.22 2.55 2.47 
Error 0.786 0.618 0.533 0.508 0.378 0.335 0.307 0.320 
D(RBE) in tumor 17.70 13.96 11.51 10.39 7.78 6.29 4.99 4.36 
Error 0.920 0.778 0.695 0.663 0.539 0.478 0.429 0.416 
Therapeutic Ratio 1.44 1.64 1.75 1.75 1.97 1.95 1.96 1.77 
 
 
 
 
 
 
 
 61
Table III-8. Different dose components for a 40 cm FluentalTM moderator. 
Depth, cm Dose components, cGy/min 
1 2 3 4 5 6 7 8 
D(RBE)fast 3.53 1.85 1.69 1.25 0.47 0.32 0.34 0.11 
Error 0.46 0.25 0.29 0.28 0.13 0.12 0.13 0.07 
D(RBE)photon 0.477 0.514 0.468 0.486 0.398 0.381 0.320 0.242 
Error 0.039 0.041 0.039 0.039 0.035 0.036 0.031 0.027 
D(RBE)14N 0.150 0.151 0.135 0.117 0.097 0.072 0.060 0.047 
Error 0.015 0.015 0.014 0.013 0.011 0.009 0.009 0.008 
D(RBE)10B in tumor 3.55 3.57 3.20 2.77 2.29 1.69 1.43 1.11 
Error 0.41 0.41 0.40 0.36 0.32 0.27 0.25 0.22 
D(RBE)10B in healthy tissue 0.347 0.348 0.312 0.270 0.224 0.165 0.139 0.109 
Error 0.01 0.014 0.013 0.012 0.011 0.009 0.008 0.007 
D(RBE) in healthy tissue 4.51 2.86 2.60 2.12 1.19 0.93 0.86 0.50 
Error 0.464 0.251 0.295 0.287 0.138 0.123 0.138 0.073 
D(RBE) in tumor 7.71 6.08 5.49 4.62 3.26 2.46 2.15 1.51 
Error 0.621 0.482 0.496 0.457 0.351 0.293 0.283 0.231 
Therapeutic Ratio 1.71 2.13 2.11 2.18 2.74 2.64 2.49 3.00 
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III – 4 – 4. Results for a heavy water moderator 
The most promising results were obtained with a heavy water moderator. Four 
different thicknesses were investigated – 25, 30, 40 and 50 cm. Neutron fluence rates 
were higher or at least of the same order of magnitude compared to other types of 
moderating materials used in this research, see Figure III-17. 
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Figure III-17. Neutron fluence rates for two different heavy water 
moderator thicknesses at a depth of 3 cm inside a brain phantom. 
 
Since heavy water is a good moderator, neutrons could significantly slow down 
even in a 25 cm layer of this material. So, the fast component of a neutron fluence rate 
was not high. Moreover, after moderating with heavy water having thickness of 40 cm or 
more the neutron fluence rate inside a brain phantom was comprised almost totally of 
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thermal neutrons. The neutron spectra for thicknesses of 25 cm and 30 cm are shown in 
Figure III-18.  
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Figure III-18. Neutron spectra for two different heavy water moderator 
thicknesses at a depth of 3 cm inside a brain phantom. 
 
Tables III-9, III-10, III-11 and III-12 show contributions of each dose component 
to the total dose for all four thicknesses of heavy water. Good neutron thermalization 
resulted in therapeutic ratios of 2 or more depending on how much moderator material 
was placed between a neutron source and the particular target at a certain depth inside a 
brain phantom. Three out of the four thicknesses were rejected for future analysis. The 
neutron spectrum from a 25 cm thick moderator still suffered from high energy neutrons 
that reduced the therapeutic ratio. Moderator thicknesses of 40 and 50 cm showed good 
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treatment abilities compared to other moderators but the neutron fluence rate was too 
low to provide treatment in a reasonable time. Thus, a heavy water moderator, having 
thickness of 30 cm, was chosen for future investigation and comparison. 
 
Table III-9. Different dose components for a 25 cm heavy water moderator. 
Depth, cm Dose components, cGy/min 
1 2 3 4 5 6 7 8 
D(RBE)fast 6.84 4.25 4.47 3.51 2.73 1.84 1.60 1.00 
Error 0.60 0.44 0.54 0.49 0.43 0.32 0.32 0.25 
D(RBE)photon 1.458 1.427 1.153 1.119 1.060 0.902 0.808 0.685 
Error 0.056 0.056 0.047 0.048 0.046 0.042 0.040 0.038 
D(RBE)14N 0.42 0.37 0.30 0.25 0.20 0.16 0.12 0.09 
Error 0.022 0.020 0.018 0.016 0.014 0.012 0.010 0.009 
D(RBE)10B in tumor 9.83 8.65 7.14 5.82 4.82 3.71 2.83 2.15 
Error 0.62 0.57 0.50 0.44 0.39 0.34 0.29 0.25 
D(RBE)10B in healthy tissue 0.96 0.844 0.697 0.568 0.470 0.362 0.276 0.209 
Error 0.02 0.019 0.017 0.015 0.013 0.011 0.010 0.008 
D(RBE) in healthy tissue 9.67 6.89 6.62 5.45 4.46 3.26 2.80 1.98 
Error 0.599 0.449 0.544 0.488 0.435 0.325 0.327 0.254 
D(RBE) in tumor 18.54 14.70 13.07 10.70 8.81 6.61 5.36 3.92 
Error 0.859 0.725 0.740 0.657 0.587 0.469 0.438 0.356 
Therapeutic Ratio 1.92 2.13 1.97 1.96 1.98 2.03 1.91 1.98 
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Table III-10. Different dose components for a 30 cm heavy water moderator. 
Depth, cm Dose components, cGy/min 
1 2 3 4 5 6 7 8 
D(RBE)fast 2.74 2.38 1.63 1.34 1.47 1.47 1.40 0.40 
Error 0.43 0.40 0.32 0.33 0.32 0.36 0.32 0.17 
D(RBE)photon 1.021 1.054 0.906 0.866 0.794 0.731 0.622 0.538 
Error 0.047 0.048 0.044 0.043 0.042 0.042 0.037 0.035 
D(RBE)14N 0.327 0.273 0.224 0.183 0.142 0.115 0.082 0.057 
Error 0.019 0.017 0.015 0.014 0.012 0.010 0.009 0.007 
D(RBE)10B in tumor 7.74 6.45 5.29 4.32 3.36 2.73 1.95 1.34 
Error 0.55 0.49 0.43 0.38 0.33 0.28 0.24 0.19 
D(RBE)10B in healthy tissue 0.755 0.629 0.516 0.421 0.327 0.266 0.190 0.131 
Error 0.02 0.016 0.014 0.013 0.011 0.009 0.008 0.006 
D(RBE) in healthy tissue 4.84 4.34 3.28 2.81 2.73 2.58 2.29 1.13 
Error 0.435 0.401 0.327 0.335 0.327 0.361 0.321 0.173 
D(RBE) in tumor 11.83 10.16 8.05 6.71 5.76 5.05 4.05 2.34 
Error 0.699 0.633 0.537 0.508 0.461 0.459 0.403 0.259 
Therapeutic Ratio 2.44 2.34 2.46 2.39 2.11 1.95 1.77 2.07 
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Table III-11. Different dose components for a 40 cm heavy water moderator. 
Depth, cm Dose components, cGy/min 
1 2 3 4 5 6 7 8 
D(RBE)fast 1.069 0.936 0.274 0.251 0.283 0.597 0.390 0.092 
Error 0.256 0.254 0.100 0.099 0.123 0.239 0.172 0.058 
D(RBE)photon 0.632 0.578 0.585 0.547 0.482 0.414 0.364 0.307 
Error 0.041 0.039 0.040 0.038 0.037 0.034 0.031 0.027 
D(RBE)14N 0.190 0.148 0.119 0.096 0.071 0.052 0.040 0.033 
Error 0.016 0.013 0.012 0.010 0.008 0.007 0.006 0.005 
D(RBE)10B in tumor 4.489 3.499 2.814 2.264 1.681 1.241 0.947 0.788 
Error 0.442 0.367 0.324 0.284 0.235 0.196 0.164 0.153 
D(RBE)10B in healthy tissue 0.438 0.341 0.274 0.221 0.164 0.121 0.092 0.077 
Error 0.015 0.012 0.011 0.009 0.008 0.007 0.005 0.005 
D(RBE) in healthy tissue 2.329 2.003 1.252 1.115 1.000 1.185 0.887 0.510 
Error 0.260 0.258 0.109 0.107 0.129 0.241 0.175 0.064 
D(RBE) in tumor 6.380 5.161 3.792 3.158 2.518 2.305 1.741 1.220 
Error 0.512 0.448 0.342 0.303 0.268 0.311 0.240 0.166 
Therapeutic Ratio 2.74 2.58 3.03 2.83 2.52 1.95 1.96 2.39 
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Table III-12. Different dose components for a 50 cm heavy water moderator. 
Depth, cm Dose components, cGy/min 
1 2 3 4 5 6 7 8 
D(RBE)fast 0.377 0.146 0.132 0.082 0.109 0.046 0.103 0.033 
Error 0.152 0.087 0.076 0.063 0.070 0.044 0.072 0.031 
D(RBE)photon 0.444 0.388 0.352 0.312 0.325 0.276 0.225 0.261 
Error 0.038 0.032 0.033 0.031 0.031 0.029 0.025 0.029 
D(RBE)14N 0.112 0.086 0.071 0.051 0.038 0.029 0.023 0.015 
Error 0.012 0.010 0.009 0.007 0.006 0.005 0.004 0.004 
D(RBE)10B in tumor 2.647 2.040 1.672 1.209 0.899 0.676 0.542 0.366 
Error 0.329 0.288 0.249 0.207 0.172 0.145 0.126 0.101 
D(RBE)10B in healthy tissue 0.258 0.199 0.163 0.118 0.088 0.066 0.053 0.036 
Error 0.011 0.010 0.008 0.007 0.006 0.005 0.004 0.003 
D(RBE) in healthy tissue 1.190 0.819 0.718 0.563 0.559 0.417 0.404 0.346 
Error 0.157 0.094 0.084 0.070 0.077 0.053 0.077 0.043 
D(RBE) in tumor 3.579 2.660 2.227 1.654 1.371 1.027 0.893 0.676 
Error 0.364 0.302 0.263 0.218 0.188 0.155 0.148 0.109 
Therapeutic Ratio 3.01 3.25 3.10 2.94 2.45 2.47 2.21 1.96 
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III – 4 – 5. Filtering experiment  
Two different moderators were selected for a filtering experiment based on the 
results presented above – heavy water and FluentalTM, both having thickness of 30 cm. 
The heavy water moderator showed relatively high therapeutic ratio with decent dose 
rates inside a brain phantom. The FluentalTM moderator didn’t provide a high therapeutic 
ratio, but dose rates were significantly higher than those for a heavy water moderator of 
the same thickness. 
The geometry used for a filtering experiment is shown in Figure III-19. 
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Figure III-19. Geometry used for a filtering experiment. 
 
Considering the information presented in Chapter III – 1 – 2, a nickel filter was 
investigated to improve spectral characteristics of moderating neutrons. Neutron 
energies were expected to shift to the epithermal region thus reducing the dose to scalp 
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and skull from thermal neutrons and increasing the therapeutic ratio for brain tissue. The 
total cross-section of nickel is on the order of few tens of barns. This suggests a neutron 
mean free path in nickel equal to 1 – 2 millimeters. Thus, the thickness of a nickel filter 
was set to at least ten neutron mean free paths or about to 2 cm. Two different filter 
positions were considered in order to investigate any differences in the resulting neutron 
spectrum. The “left” position (Nickel filter – 1 on Figure III-19) when the filter was 
placed next to the neutron source and the “intermediate” position (Nickel filter – 2 on 
Figure III-19), when the filter was placed inside the moderator medium at a 7-cm depth. 
The total neutron fluence rates for both positions are shown in Figures III-20 and III-21. 
The filtered fluence rates came out to be lower by 20 – 30 percent compared to those 
obtained without filtering. This is because of the significantly higher nickel absorption 
cross-section compared to that of heavy water or FluentalTM, see Figures III-3 and III-5 
above. Moreover, the total fluence rate obtained with a filter in the “intermediate” 
position is lower than the fluence rate when a filter in the “left” position was used. This 
was due to the moderation of incident neutrons. Neutrons hitting a filter in the 
“intermediate” position had lower average energies because of slowing down in 7 cm of 
moderation material. The lower neutron energy means the higher nickel absorption 
cross-section and, thus, the resulting lower fluence rate. 
The calculated results for different dose components for both moderators and two 
different geometries are given in Tables III-13-16. A nickel filter, when used, replaced a 
part of a moderating material. This influences the fluence rate in two competing ways – 
reducing a total fluence rate due to absorption, as it is described above, but also 
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increasing the fast part of a fluence rate due to the smaller moderator thickness. Note 
that the total doses to a tumor and healthy tissue are reduced for both moderators 
because of the lower fluence rate of thermal neutrons. 
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Figure III-20. The neutron fluence rate for a FluentalTM moderator with 
and without a nickel filter. 
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Figure III-21. The neutron fluence rate for a heavy water moderator with 
and without a nickel filter. 
 
The dose from fast neutrons is also reduced for a FluentalTM moderator, but for heavy 
water it increased. This is because heavy water is a much better moderator than the 
FluentalTM, so decreasing of moderator thickness significantly increases the fast fluence 
rate component. 
Another calculation was made to see a difference between natural nickel filter 
and a 60Ni filter. Ni-60 has several benefits compared to natural nickel and that was 
discussed in Chapter III-1-2. One of them is a lower neutron absorption cross-section for 
the whole energy range compared to natural nickel. This leads to a higher resulting 
neutron fluence rate and a lower photon dose, see Figure III-22 and Table III-17. Also, 
60Ni has a much lower scattering cross-section compared to natural nickel for low-
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energy neutrons. This means the dose to tissue due to fast neutrons will be higher if the 
60Ni filter is used instead of natural nickel, see Table III-17. For these reasons, 60Ni 
yields a higher therapeutic ratio compared to a natural nickel filter in the same geometry. 
However, the fluence rate is still much less than that for the geometry with no filter. 
Thus, the use of a nickel filter didn’t show any benefits in term of therapeutic 
ratios, and, since the total fluence rate was also reduced, the moderator assemblies 
containing no filter were chosen for a final comparison. 
 
Table III-13. Different dose components for a 28 cm heavy water moderator and 
2 cm nickel filter in the “left” position. 
 
Depth, cm Dose components, cGy/min 
1 2 3 4 5 6 7 8 
D(RBE)fast 3.315 2.873 1.816 1.571 1.299 0.920 0.939 1.052 
Error 0.307 0.311 0.240 0.226 0.215 0.183 0.175 0.207 
D(RBE)photon 1.332 1.314 1.161 1.108 0.975 0.916 0.826 0.760 
Error 0.041 0.040 0.038 0.037 0.035 0.034 0.032 0.031 
D(RBE)14N 0.257 0.218 0.178 0.146 0.119 0.092 0.071 0.054 
Error 0.013 0.012 0.010 0.009 0.008 0.007 0.006 0.005 
D(RBE)10B in tumor 6.076 5.165 4.204 3.450 2.806 2.184 1.679 1.270 
Error 0.363 0.324 0.288 0.253 0.225 0.191 0.165 0.140 
D(RBE)10B in healthy tissue 0.592 0.504 0.410 0.336 0.274 0.213 0.164 0.124 
Error 0.012 0.011 0.010 0.008 0.008 0.006 0.005 0.005 
D(RBE) in healthy tissue 5.496 4.910 3.564 3.160 2.666 2.140 1.999 1.990 
Error 0.310 0.314 0.244 0.229 0.218 0.186 0.178 0.209 
D(RBE) in tumor 10.98 9.57 7.36 6.27 5.20 4.11 3.51 3.14 
Error 0.48 0.45 0.38 0.34 0.31 0.27 0.24 0.25 
Therapeutic Ratio 2.00 1.95 2.06 1.99 1.95 1.92 1.76 1.58 
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Table III-14. Different dose components for a 28 cm heavy water moderator 
and 2 cm nickel filter in the “intermediate” position. 
 
Depth, cm Dose components, cGy/min 
1 2 3 4 5 6 7 8 
D(RBE)fast 3.334 2.310 1.550 1.712 1.477 1.030 0.978 0.721 
Error 0.326 0.255 0.216 0.251 0.237 0.196 0.196 0.150 
D(RBE)photon 1.332 1.347 1.179 1.126 1.005 0.905 0.779 0.709 
Error 0.041 0.042 0.040 0.038 0.036 0.035 0.031 0.030 
D(RBE)14N 0.217 0.191 0.157 0.132 0.103 0.083 0.066 0.046 
Error 0.012 0.011 0.009 0.009 0.007 0.007 0.006 0.005 
D(RBE)10B in tumor 5.141 4.519 3.703 3.129 2.445 1.966 1.563 1.080 
Error 0.330 0.304 0.266 0.241 0.208 0.187 0.162 0.130 
D(RBE)10B in healthy tissue 0.501 0.441 0.361 0.305 0.238 0.192 0.152 0.105 
Error 0.011 0.010 0.009 0.008 0.007 0.006 0.005 0.004 
D(RBE) in healthy tissue 5.385 4.289 3.246 3.276 2.824 2.210 1.976 1.581 
Error 0.329 0.259 0.220 0.254 0.240 0.199 0.199 0.153 
D(RBE) in tumor 10.03 8.37 6.59 6.10 5.03 3.98 3.39 2.56 
Error 0.47 0.40 0.35 0.35 0.32 0.27 0.26 0.20 
Therapeutic Ratio 1.86 1.95 2.03 1.86 1.78 1.80 1.71 1.62 
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Table III-15. Different dose components for a 28 cm FluentalTM moderator 
and 2 cm nickel filter in the “left” position. 
 
Depth, cm Dose components, cGy/min 
1 2 3 4 5 6 7 8 
D(RBE)fast 8.003 6.130 4.542 3.522 2.612 1.886 1.814 1.508 
Error 0.470 0.441 0.392 0.340 0.299 0.256 0.270 0.251 
D(RBE)photon 0.787 0.719 0.687 0.745 0.613 0.560 0.499 0.416 
Error 0.035 0.033 0.032 0.033 0.030 0.029 0.027 0.024 
D(RBE)14N 0.203 0.208 0.194 0.178 0.153 0.121 0.102 0.078 
Error 0.012 0.012 0.011 0.011 0.010 0.009 0.008 0.007 
D(RBE)10B in tumor 4.791 4.912 4.593 4.214 3.625 2.853 2.419 1.852 
Error 0.335 0.336 0.319 0.306 0.281 0.244 0.227 0.191 
D(RBE)10B in healthy tissue 0.467 0.479 0.448 0.411 0.353 0.278 0.236 0.181 
Error 0.011 0.011 0.011 0.010 0.009 0.008 0.008 0.006 
D(RBE) in healthy tissue 9.460 7.536 5.870 4.856 3.732 2.844 2.650 2.183 
Error 0.472 0.442 0.394 0.342 0.301 0.258 0.272 0.252 
D(RBE) in tumor 13.78 11.97 10.02 8.66 7.00 5.42 4.83 3.85 
Error 0.58 0.56 0.51 0.46 0.41 0.36 0.35 0.32 
Therapeutic Ratio 1.46 1.59 1.71 1.78 1.88 1.91 1.82 1.77 
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Table III-16. Different dose components for a 28 cm FluentalTM moderator 
and 2 cm nickel filter in the “intermediate” position. 
 
Depth, cm Dose components, cGy/min 
1 2 3 4 5 6 7 8 
D(RBE)fast 8.189 6.075 4.117 3.093 1.978 2.205 1.701 1.239 
Error 0.534 0.478 0.394 0.362 0.281 0.330 0.266 0.232 
D(RBE)photon 0.715 0.726 0.757 0.731 0.688 0.558 0.532 0.453 
Error 0.035 0.036 0.036 0.037 0.036 0.031 0.031 0.028 
D(RBE)14N 0.190 0.202 0.189 0.168 0.143 0.117 0.089 0.071 
Error 0.013 0.013 0.012 0.011 0.011 0.009 0.008 0.007 
D(RBE)10B in tumor 4.504 4.786 4.470 3.963 3.382 2.771 2.099 1.679 
Error 0.356 0.366 0.348 0.321 0.298 0.264 0.225 0.198 
D(RBE)10B in healthy tissue 0.439 0.467 0.436 0.386 0.330 0.270 0.205 0.164 
Error 0.012 0.012 0.012 0.011 0.010 0.009 0.008 0.007 
D(RBE) in healthy tissue 9.534 7.470 5.498 4.378 3.138 3.150 2.526 1.926 
Error 0.535 0.479 0.396 0.364 0.284 0.332 0.268 0.234 
D(RBE) in tumor 13.60 11.79 9.53 7.95 6.19 5.65 4.42 3.44 
Error 0.64 0.60 0.53 0.49 0.41 0.42 0.35 0.31 
Therapeutic Ratio 1.43 1.58 1.73 1.82 1.97 1.79 1.75 1.79 
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Table III-17. Different dose components for a 28 cm heavy water moderator 
and 2 cm 60Ni filter in the “left” position. 
 
Depth, cm Dose components, cGy/min 
1 2 3 4 5 6 7 8 
D(RBE)fast 3.282 2.715 2.178 1.885 1.243 1.120 0.786 0.992 
Error 0.349 0.352 0.329 0.297 0.260 0.238 0.183 0.243 
D(RBE)photon 1.053 1.003 0.947 0.826 0.769 0.730 0.623 0.565 
Error 0.044 0.043 0.042 0.039 0.039 0.037 0.035 0.033 
D(RBE)14N 0.278 0.231 0.193 0.156 0.129 0.092 0.074 0.057 
Error 0.016 0.014 0.013 0.011 0.010 0.008 0.007 0.006 
D(RBE)10B in tumor 6.587 5.470 4.559 3.685 3.058 2.174 1.749 1.342 
Error 0.453 0.405 0.357 0.312 0.279 0.228 0.203 0.173 
D(RBE)10B in healthy tissue 0.642 0.533 0.444 0.359 0.298 0.212 0.171 0.131 
Error 0.015 0.014 0.012 0.010 0.009 0.008 0.007 0.006 
D(RBE) in healthy tissue 5.256 4.482 3.763 3.226 2.439 2.154 1.653 1.745 
Error 0.353 0.355 0.332 0.300 0.264 0.241 0.187 0.246 
D(RBE) in tumor 11.20 9.42 7.88 6.55 5.20 4.12 3.23 2.96 
Error 0.57 0.54 0.49 0.43 0.38 0.33 0.28 0.30 
Therapeutic Ratio 2.13 2.10 2.09 2.03 2.13 1.91 1.95 1.69 
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Figure III-22. Comparison of natural nickel and 60Ni filters. 
 
III – 4 – 6. Comparison of the most suitable moderators 
The two different geometries that showed the most promise were selected based 
on the calculated results. The first moderating geometry is 30 cm of heavy water. The 
second geometry includes a 40 cm thick FluentalTM moderator. These two geometries 
showed very similar results see Table III-8 and Table III-10 above. Thermal neutrons 
and photons produced a lower dose to healthy tissue in both cases compared to that from 
fast neutrons. This is especially appreciable for a FluentalTM moderator and shallow 
depths inside a brain phantom. The main problem for both geometries is the fast neutron 
dose. The larger moderator thickness provides less fast neutrons but increases a 
treatment time. Thus, a compromise must be found between these two quantities. 
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One of the most significant clinical requirements, namely that the dose to the 
healthy brain tissue must be kept below its tolerance limit, has to be considered. 
According to the protocol used at the Brookhaven Medical Research Reactor (BMRR), 
the maximum dose to the normal brain is set to 12.5 RBEGy (Bleuel et al 1998), which 
for the conditions of these two experiments, supposing a 60 μA beam current, would be 
reached for a treatment time of 258 min with a heavy water moderator and 277 min with 
a FluentalTM moderator. The RBE-dose rates obtained from calculations are plotted in  
Figures III-23 and III-24. For a heavy water moderator the advantage depth is 6.2 cm 
and, if a FluentalTM moderator is used, this depth is 4 cm. Thus, heavy water looks 
preferable to a FluentalTM moderator in terms of using it for boron neutron capture 
therapy. Combinations of FluentalTM and heavy water could be used but only small gains 
could be realized. 
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Figure III-23. RBE-dose for a 258 min treatment with a heavy water 
moderator. 
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Figure III-24. RBE-dose for a 277 min treatment with a FluentalTM 
moderator. 
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CHAPTER IV 
CONCLUSIONS AND DISCUSSION 
 
Boron neutron capture therapy (BNCT) is under active investigation all over the 
world. Historically the best source of neutrons was a nuclear reactor. However, 
disadvantages of reactor are the high capital costs are very high and reactors are too 
complicated for an ordinary clinic to operate, so these clinics cannot afford to build and 
maintain a small nuclear reactor to use as a neutron source. 
Another approach to this problem is to use particle accelerators. These machines 
can accelerate protons or deuterons to the required energies for the reaction and the 
bombarded target emits neutrons. If the beam current and reaction cross-section is high 
then the neutrons can be obtained at rates and energy levels appropriate for BNCT. 
There are a number of advantages of using accelerators as a neutron source for BNCT. 
They are cheaper, easier to operate, and are pose less overall risk than nuclear reactors. 
Accelerator neutron sources are well understood and implemented in a number of 
research facilities (Wang et al 1989). 
This dissertation has produced a first look at using the particular GE PETtrace 
cyclotron with 18O target for BNCT. Many facilities, such as nuclear pharmacies and 
hospitals are using this cyclotron for medical radionuclide production. These cyclotrons 
are designed mostly for fluorodeoxyglucose (FDG) production. FDG is manufactured in 
an automated synthesis unit from 18F. This nuclide is produced in a cyclotron by proton 
bombardment of enriched water (18O). The efficiency of cyclotron use may be 
 
 81
significantly increased if unused neutrons could be utilized for BNCT at the same time 
as radionuclide production. 
While bombarding with protons the 18O target emits neutrons. The resulting dose 
from the radiation emitted from the target is evaluated using the Monte Carlo radiation 
transport code MCNP at several depths in a brain phantom for several scattering 
geometries. Each geometry includes a moderator assembly surrounded by a thick carbon 
reflector. 
The moderator assembly consists of an aluminum container filled with a 
moderating material. Several different types of materials were investigated to moderate 
neutrons to the epithermal energies: light water, carbon, heavy water and FluentalTM that 
consists of aluminum, fluorine and natural lithium (Auterinen et al 1993). Various 
thicknesses of moderating material were used in this study. The thickness that provided 
the lowest fast-neutrons contribution to the total fluence rate compared to the low-energy 
component and that allowed delivery of the necessary dose for the reasonable time was 
investigated. 
The proposed carbon reflector consists of two major parts: a side-reflector and a 
back-reflector. The reflector decreases the neutron leaking and allows getting a higher 
neutron fluence rate inside a brain phantom. After the scoping calculations using MCNP 
the 30-cm thick side-reflector and the 22-cm thick back-reflector were chosen for all 
further analysis. 
Neutrons emitted from the 18O target had a certain energy spectrum and angular 
distribution. These data were used to define the neutron source in MCNP calculations. 
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The 18O target was also considered as a strong isotropically-emitting gamma-source with 
known energy spectrum. The dose rates from the neutron and gamma irradiation were 
determined at different depths inside a brain phantom using MCNP. The phantom was 
filled with a special composition to simulate brain tissue (ICRU-44 1989) and the tally 
cells were   0.5 cm diameter spheres at depths of 1, 2, 3, 4, 5, 6, 7 and 8 cm. Most 
neutrons have been thermalized at the tally depths. So, to know the total dose delivered 
to the tumor and the healthy tissue, other components of the total dose were calculated. 
There are two principal capture reactions for thermal neutrons in tissue – 1H(n,γ)2H and 
14N(n,p)14C (Turner 1995). These reactions occur both in healthy tissue and tumor and 
are unwanted irradiation. The main dose component to the tumor, which should be 
maximized, is the neutron capture reaction with 10B. The charged particles produced in 
this reaction, 10B(n,α)7Li, have the total kinetic energy of 2.34 MeV on average and their 
range in tissue of about 10 μm, the order of the size of a tumor cell. To maximize dose to 
the tumor and keep the dose to healthy tissue as low as possible, 10B concentrations in 
normal tissue must be much lower than that within the tumor. B-10 concentrations in 
healthy tissue of 11.4 ppm and within the tumor of 40 ppm were assumed (Coderre et al 
1998). 
Geometries with several moderating materials having different thicknesses were 
investigated using MCNP. Two different thicknesses, 25 cm and 30 cm, were 
investigated for a light water moderator. The results showed that light water heavily 
absorbed neutrons. Thus, the resulting neutron fluence rates came out to be very low; 
almost two orders lower than it is desirable for BNCT. Since the neutron fluence rate is 
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so low, the boron capture provided only a little contribution to the total dose and the 
therapeutic ratio, which mainly depends on the dose component coming from the 
neutron capture on boron, was close to 1. Thus, light water cannot be used as a part of 
the irradiation system for BNCT. 
Two thicknesses of carbon moderator were also considered, 30 cm and 40 cm. A 
30-cm thick carbon moderator does not provide sufficient moderation of neutrons, so 
healthy tissue received a significant dose from fast neutrons and as a result the 
therapeutic ratio was less than 2. A carbon thickness of 40 cm was sufficient to moderate 
neutrons, but the resulting neutron fluence rates were barely higher than those obtained 
with a light water moderator. Although the therapeutic ratio was relatively high, this 
moderating material cannot be used for BNCT, since the treatment time would be 740 
minutes, which is extremely high. 
Another popular type of a BNCT moderator, called FluentalTM, was investigated. 
Two different thicknesses of this moderating material were considered. The first 
calculation was done for a moderator thickness of 30 cm, and the second calculation for 
40 cm of FluentalTM. The fluence rates obtained were much higher compared to those of 
carbon. The use of FluentalTM instead of carbon provided a factor of 1.5 – 2 increase in a 
total fluence rate but, since the FluentalTM has lower moderation ability, the resulting 
neutron spectrum suffered from fast neutrons. This results in a huge contribution to the 
total dose in healthy tissue from fast neutrons. Thus, the therapeutic ratio was less than 2 
for a 30-cm thick FluentalTM moderator, which is not enough for successful tumor 
treatment. The therapeutic ratio for a 40-cm thick moderator was slightly higher than 2, 
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and the resulting neutron fluence rate provided the treatment time of 277 minutes, which 
is probably reasonable. Thus, this geometry was considered as one of the possible 
choices for BNCT. 
The most promising results were obtained with a heavy water moderator. Four 
different thicknesses were investigated – 25, 30, 40 and 50 cm. Neutron fluence rates 
came out to be higher or at least of the same order of magnitude compared to other types 
of moderating materials. A 25 cm thickness didn’t provide sufficient moderation of 
neutrons, thus the therapeutic ratio was less than 2. Heavy water moderators with 
thicknesses of 40 cm and 50 cm could significantly thermalize neutrons, but the resulting 
fluence rates inside brain were low because of the large source-target distance. The 
treatment time for a 40-cm thick heavy water moderator would be 537 minutes and for a 
50-cm thick – 1050 minutes. 
The best results were obtained using a 30-cm thick heavy water moderator. This 
moderating material provided a relatively high therapeutic ratio for a reasonable 
treatment time compared to other geometries. Results showed that using of a PETtrace 
cyclotron in this configuration provides a therapeutic ratio of about 2.4 for depths up to 4 
cm inside a brain phantom. A treatment time using a heavy water moderator in this 
particular geometry would be 258 minutes, assuming a 60 μA beam current. For this 
treatment time, healthy tissue would get a dose of 12.5 RBEGy and a shallow tumor 
would get a dose of approximately 30 RBEGy. These results for heavy water appear 
preferable to a 40-cm thick FluentalTM moderator. 
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Several calculations were carried out to investigate the advantage of using 
filtering material such as natural nickel. Two different moderators were selected for a 
filtering experiment – heavy water and FluentalTM, both having thickness of 30 cm. A   
2-cm thick nickel filter was placed at two different depths inside a moderator assembly. 
As a result, neutron energies were expected to shift to the epithermal region thus 
reducing the dose to scalp and skull from thermal neutrons and increasing the therapeutic 
ratio for brain tissue. The filtered fluence rates as well as the therapeutic ratios were 
lower by 20 – 30 percent compared to those obtained without filtering. Another 
calculation was made to see a difference between natural nickel filter and a 60Ni filter 
that has several benefits compared to natural nickel. The use of a 60Ni filter resulted in a 
higher therapeutic ratio compared to the geometry with a natural nickel filter, but it was 
still much less than that for the geometry with no filter. Thus, the use of a nickel filter 
didn’t show any benefits in term of therapeutic ratios, and, since the total fluence rate 
was also reduced, the moderator assembly containing 30-cm thick heavy water and no 
filter was chosen as most suitable for BNCT using GE PETtrace cyclotron. 
Although some positive results in using of this cyclotron were showed in this 
research, the main disadvantage of GE PETtrace as a neutron source is a low neutron 
fluence rate. But further increase of a beam current up to 120 μA that proposed by GE 
should significantly improve the beam quality or improve the treatment time. This lack 
of neutrons and the condition of a reasonable treatment time have restricted a moderator 
thickness, thus almost all of the moderating geometries considered suffered from fast 
neutrons. These neutrons provided significant dose to healthy tissue reducing the 
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therapeutic ratio. Increasing of a beam current should improve the beam quality by using 
a moderator of a larger thickness, for example 50 cm. These conditions may be 
considered in a future work. The therapeutic ratio in this case would be around 3 for the 
approximately the same treatment time, see Table III-12 above. Also, the photoneutron 
reaction with heavy water, which can provide additional neutrons to the beam, has not 
been investigated in this research and thus may be considered for a future work. 
The results suggest that it is possible to use this particular cyclotron with this 
target for the tumor treatment. The data presented in this dissertation allow the 
conclusion that this type of neutron source should provide acceptable doses and 
treatment times for tumor irradiation at a depth of up to 4-5 cm inside the brain phantom 
where the therapeutic ratio is higher than 2. 
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APPENDIX A 
MCNP INPUT FILE FOR THE NEUTRON DOSE CALCULATION 
 
Neutron source with 30 cm D2O moderator thickness 
1 8 -1 -1 29 -10 imp:n,p=1 $water (target) 
2 12 -7.85 -1 10 -11 imp:n,p=1 $steel cover 
3 1 -11.34 -2 11 -12 imp:n,p=1 $lead shield 
4 10 -1 13 -3 -16 -14 imp:n,p=1 $moderator 
5 3 -2.7 12 -4 -17 -15 #4 imp:n,p=1 $aluminum container 
6 5 -2.267 (5 -6 7 -8 12 -15 4):(5 -6 7 -8 -12 11 2): 
     (5 -6 7 -8 9 -11 1) imp:n,p=1 $graphite reflector 
7 1 -11.34 -4 17 -15 imp:n,p=1 $lead collimator 
8 12 -7.85 5 -6 7 -8 18 -9 imp:n,p=1 $steel wall 
9 13 -1.04 -20 #10 #14 #15 #16 #17 #18 #19 #20 imp:n,p=1 $phantom 
10 13 -1.04 -21 imp:n,p=1 $tumor at 1 cm 
14 13 -1.04 -22 imp:n,p=1 $tumor at 2 cm 
15 13 -1.04 -23 imp:n,p=1 $tumor at 3 cm 
16 13 -1.04 -24 imp:n,p=1 $tumor at 4 cm 
17 13 -1.04 -25 imp:n,p=1 $tumor at 5 cm 
18 13 -1.04 -26 imp:n,p=1 $tumor at 6 cm 
19 13 -1.04 -27 imp:n,p=1 $tumor at 7 cm 
20 13 -1.04 -28 imp:n,p=1 $tumor at 8 cm 
21 7 -0.001205 (-5:6:-7:8:-18:15) -19 #9 #10 #14 #15 #16 
     #17 #18 #19 #20 imp:n,p=1 $air 
12 0 19 imp:n,p=0 $vacuum 
13 7 -0.001205 -1 9 -29 imp:n,p=1$ target air 
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1 cy 5 
2 cy 10 
3 cy 15 
4 cy 16 
5 px -46 
6 px 46 
7 pz -46 
8 pz 46 
9 py -17 
10 py 4 
11 py 5 
12 py 8 
13 py 9 
14 py 39 
15 py 40 
16 ky 60 0.3333333 -1 
17 ky 61 0.3333333 -1 
18 py -18 
19 sy 10 100 
20 SQ 0.010412328 0.021626297 0.014515894 0 0 0 -1 0 46 0 
21 sy 41.2 0.25 
22 sy 42.2 0.25 
23 sy 43.2 0.25 
24 sy 44.2 0.25 
25 sy 45.2 0.25 
26 sy 46.2 0.25 
27 sy 47.2 0.25 
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28 sy 48.2 0.25 
29 py 2 
 
mode n p 
VOL 8j 2306.889162 11j 
AREA 19j 862.075375 9j 
c====================================================================== 
c                            Source 
c====================================================================== 
sdef par=1 erg fdir d2 pos=0 2.5 0 dir=d1 vec=0 1 0 
si1 L 0.98481 0.86603 0.64279 0.34202 0 -0.34202 -0.64279 -0.86603 -
0.98481 
sp1 0.145529955 0.138397972 0.127134436 0.115001384 0.104331861 
0.096531728 
     0.092077857 0.090519033 0.090475774 
ds2 s d3 d4 d5 d6 d7 d8 d9 d10 d11 
# si3 sp3 
0.000001 0 
1 0.048048 
2 0.044712 
3 0.026989 
4 0.013585 
5 0.006713 
6 0.003139 
7 0.001457 
8 0.000618 
9 0.000269 
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# si4 sp4 
0.000001 0 
1 0.046044 
2 0.042598 
3 0.025569 
4 0.012800 
5 0.006291 
6 0.002927 
7 0.001351 
8 0.000569 
9 0.000246 
# si5 sp5 
0.000001 0 
1 0.042772 
2 0.039255 
3 0.023380 
4 0.011590 
5 0.005642 
6 0.002601 
7 0.001188 
8 0.000495 
9 0.000212 
# si6 sp6 
0.000001 0 
1 0.039182 
2 0.035638 
3 0.021037 
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4 0.010308 
5 0.004961 
6 0.002261 
7 0.001019 
8 0.000419 
9 0.000177 
# si7 sp7 
0.000001 0 
1 0.035964 
2 0.032432 
3 0.018980 
4 0.009206 
5 0.004385 
6 0.001977 
7 0.000880 
8 0.000358 
9 0.000149 
# si8 sp8 
0.000001 0 
1 0.033545 
2 0.030057 
3 0.017475 
4 0.008429 
5 0.003992 
6 0.001789 
7 0.000792 
8 0.000320 
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9 0.000133 
# si9 sp9 
0.000001 0 
1 0.032088 
2 0.028664 
3 0.016612 
4 0.008018 
5 0.003799 
6 0.001704 
7 0.000757 
8 0.000307 
9 0.000128 
# si10 sp10 
0.000001 0 
1 0.031496 
2 0.028138 
3 0.016309 
4 0.007909 
5 0.003767 
6 0.001698 
7 0.000761 
8 0.000311 
9 0.000131 
# si11 sp11 
0.000001 0 
1 0.031407 
2 0.028095 
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3 0.016306 
4 0.007936 
5 0.003793 
6 0.001716 
7 0.000772 
8 0.000317 
9 0.000134 
c====================================================================== 
c                                 Tumor at 1 cm 
c====================================================================== 
c Photon Fluence in tumor 
f4:p 10 
fm4 3.21e+11 
E4 0.01 0.1 0.2 0.5 1 2 5 10 
c Photon RBE-Dose in tumor (rem/hr) 
f14:p 10 
fm14 3.21e+11 
de14 0.01 0.015 0.02 0.03 0.04 0.05 0.06 0.08 0.1 0.15 0.2 0.3 0.4 0.5 
     0.6 0.8 1 1.5 2 3 4 5 6 8 10 
df14 2.78e-6 1.11e-6 5.88e-7 2.56e-7 1.56e-7 1.2e-7 1.11e-7 1.2e-7 
     1.47e-7 2.38e-7 3.45e-7 5.56e-7 7.69e-7 9.09e-7 1.14e-6 1.47e-6 
     1.79e-6 2.44e-6 3.03e-6 4e-6 4.76e-6 5.56e-6 6.25e-6 7.69e-6 
9.09e-6 
c Neutron Fluence in tumor 
f24:n 10 
fm24 3.21e+11 
E24 0.0000005 0.000001 0.00001 0.0001 .001 .01 .1 1 10 
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c RBE-Dose in tumor (rem/hr) 
f34:n 10 
fm34 3.21e+11 
de34 2.5e-8 1e-7 1e-6 1e-5 1e-4 1e-3 1e-2 1e-1 5e-1 1 2.5 5 7 10 
df34 3.67e-6 3.67e-6 4.46e-6 4.54e-6 4.18e-6 3.76e-6 3.56e-6 2.17e-5 
     9.26e-5 1.32e-4 1.25e-4 1.56e-4 1.47e-4 1.47e-4 
c====================================================================== 
c                                 Tumor at 2 cm 
c====================================================================== 
c Photon Fluence in tumor 
f44:p 14 
fm44 3.21e+11 
E44 0.01 0.1 0.2 0.5 1 2 5 10 
c Photon RBE-Dose in tumor (rem/hr) 
f54:p 14 
fm54 3.21e+11 
de54 0.01 0.015 0.02 0.03 0.04 0.05 0.06 0.08 0.1 0.15 0.2 0.3 0.4 0.5 
     0.6 0.8 1 1.5 2 3 4 5 6 8 10 
df54 2.78e-6 1.11e-6 5.88e-7 2.56e-7 1.56e-7 1.2e-7 1.11e-7 1.2e-7 
     1.47e-7 2.38e-7 3.45e-7 5.56e-7 7.69e-7 9.09e-7 1.14e-6 1.47e-6 
     1.79e-6 2.44e-6 3.03e-6 4e-6 4.76e-6 5.56e-6 6.25e-6 7.69e-6 
9.09e-6 
c Neutron Fluence in tumor 
f64:n 14 
fm64 3.21e+11 
E64 0.0000005 0.000001 0.00001 0.0001 .001 .01 .1 1 10 
c RBE-Dose in tumor (rem/hr) 
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f74:n 14 
fm74 3.21e+11 
de74 2.5e-8 1e-7 1e-6 1e-5 1e-4 1e-3 1e-2 1e-1 5e-1 1 2.5 5 7 10 
df74 3.67e-6 3.67e-6 4.46e-6 4.54e-6 4.18e-6 3.76e-6 3.56e-6 2.17e-5 
     9.26e-5 1.32e-4 1.25e-4 1.56e-4 1.47e-4 1.47e-4 
c====================================================================== 
c                                 Tumor at 3 cm 
c====================================================================== 
c Photon Fluence in tumor 
f84:p 15 
fm84 3.21e+11 
E84 0.01 0.1 0.2 0.5 1 2 5 10 
c Photon RBE-Dose in tumor (rem/hr) 
f94:p 15 
fm94 3.21e+11 
de94 0.01 0.015 0.02 0.03 0.04 0.05 0.06 0.08 0.1 0.15 0.2 0.3 0.4 0.5 
     0.6 0.8 1 1.5 2 3 4 5 6 8 10 
df94 2.78e-6 1.11e-6 5.88e-7 2.56e-7 1.56e-7 1.2e-7 1.11e-7 1.2e-7 
     1.47e-7 2.38e-7 3.45e-7 5.56e-7 7.69e-7 9.09e-7 1.14e-6 1.47e-6 
     1.79e-6 2.44e-6 3.03e-6 4e-6 4.76e-6 5.56e-6 6.25e-6 7.69e-6 
9.09e-6 
c Neutron Fluence in tumor 
f104:n 15 
fm104 3.21e+11 
E104 0.0000005 0.000001 0.00001 0.0001 .001 .01 .1 1 10 
c RBE-Dose in tumor (rem/hr) 
f114:n 15 
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fm114 3.21e+11 
de114 2.5e-8 1e-7 1e-6 1e-5 1e-4 1e-3 1e-2 1e-1 5e-1 1 2.5 5 7 10 
df114 3.67e-6 3.67e-6 4.46e-6 4.54e-6 4.18e-6 3.76e-6 3.56e-6 2.17e-5 
     9.26e-5 1.32e-4 1.25e-4 1.56e-4 1.47e-4 1.47e-4 
c====================================================================== 
c                                 Tumor at 4 cm 
c====================================================================== 
c Photon Fluence in tumor 
f124:p 16 
fm124 3.21e+11 
E124 0.01 0.1 0.2 0.5 1 2 5 10 
c Photon RBE-Dose in tumor (rem/hr) 
f134:p 16 
fm134 3.21e+11 
de134 0.01 0.015 0.02 0.03 0.04 0.05 0.06 0.08 0.1 0.15 0.2 0.3 0.4 0.5 
     0.6 0.8 1 1.5 2 3 4 5 6 8 10 
df134 2.78e-6 1.11e-6 5.88e-7 2.56e-7 1.56e-7 1.2e-7 1.11e-7 1.2e-7 
     1.47e-7 2.38e-7 3.45e-7 5.56e-7 7.69e-7 9.09e-7 1.14e-6 1.47e-6 
     1.79e-6 2.44e-6 3.03e-6 4e-6 4.76e-6 5.56e-6 6.25e-6 7.69e-6 
9.09e-6 
c Neutron Fluence in tumor 
f144:n 16 
fm144 3.21e+11 
E144 0.0000005 0.000001 0.00001 0.0001 .001 .01 .1 1 10 
c RBE-Dose in tumor (rem/hr) 
f154:n 16 
fm154 3.21e+11 
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de154 2.5e-8 1e-7 1e-6 1e-5 1e-4 1e-3 1e-2 1e-1 5e-1 1 2.5 5 7 10 
df154 3.67e-6 3.67e-6 4.46e-6 4.54e-6 4.18e-6 3.76e-6 3.56e-6 2.17e-5 
     9.26e-5 1.32e-4 1.25e-4 1.56e-4 1.47e-4 1.47e-4 
c====================================================================== 
c                                 Tumor at 5 cm 
c====================================================================== 
c Photon Fluence in tumor 
f164:p 17 
fm164 3.21e+11 
E164 0.01 0.1 0.2 0.5 1 2 5 10 
c Photon RBE-Dose in tumor (rem/hr) 
f174:p 17 
fm174 3.21e+11 
de174 0.01 0.015 0.02 0.03 0.04 0.05 0.06 0.08 0.1 0.15 0.2 0.3 0.4 0.5 
     0.6 0.8 1 1.5 2 3 4 5 6 8 10 
df174 2.78e-6 1.11e-6 5.88e-7 2.56e-7 1.56e-7 1.2e-7 1.11e-7 1.2e-7 
     1.47e-7 2.38e-7 3.45e-7 5.56e-7 7.69e-7 9.09e-7 1.14e-6 1.47e-6 
     1.79e-6 2.44e-6 3.03e-6 4e-6 4.76e-6 5.56e-6 6.25e-6 7.69e-6 
9.09e-6 
c Neutron Fluence in tumor 
f184:n 17 
fm184 3.21e+11 
E184 0.0000005 0.000001 0.00001 0.0001 .001 .01 .1 1 10 
c RBE-Dose in tumor (rem/hr) 
f194:n 17 
fm194 3.21e+11 
de194 2.5e-8 1e-7 1e-6 1e-5 1e-4 1e-3 1e-2 1e-1 5e-1 1 2.5 5 7 10 
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df194 3.67e-6 3.67e-6 4.46e-6 4.54e-6 4.18e-6 3.76e-6 3.56e-6 2.17e-5 
     9.26e-5 1.32e-4 1.25e-4 1.56e-4 1.47e-4 1.47e-4 
c====================================================================== 
c                                 Tumor at 6 cm 
c====================================================================== 
c Photon Fluence in tumor 
f204:p 18 
fm204 3.21e+11 
E204 0.01 0.1 0.2 0.5 1 2 5 10 
c Photon RBE-Dose in tumor (rem/hr) 
f214:p 18 
fm214 3.21e+11 
de214 0.01 0.015 0.02 0.03 0.04 0.05 0.06 0.08 0.1 0.15 0.2 0.3 0.4 0.5 
     0.6 0.8 1 1.5 2 3 4 5 6 8 10 
df214 2.78e-6 1.11e-6 5.88e-7 2.56e-7 1.56e-7 1.2e-7 1.11e-7 1.2e-7 
     1.47e-7 2.38e-7 3.45e-7 5.56e-7 7.69e-7 9.09e-7 1.14e-6 1.47e-6 
     1.79e-6 2.44e-6 3.03e-6 4e-6 4.76e-6 5.56e-6 6.25e-6 7.69e-6 
9.09e-6 
c Neutron Fluence in tumor 
f224:n 18 
fm224 3.21e+11 
E224 0.0000005 0.000001 0.00001 0.0001 .001 .01 .1 1 10 
c RBE-Dose in tumor (rem/hr) 
f234:n 18 
fm234 3.21e+11 
de234 2.5e-8 1e-7 1e-6 1e-5 1e-4 1e-3 1e-2 1e-1 5e-1 1 2.5 5 7 10 
df234 3.67e-6 3.67e-6 4.46e-6 4.54e-6 4.18e-6 3.76e-6 3.56e-6 2.17e-5 
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     9.26e-5 1.32e-4 1.25e-4 1.56e-4 1.47e-4 1.47e-4 
c====================================================================== 
c                                 Tumor at 7 cm 
c====================================================================== 
c Photon Fluence in tumor 
f244:p 19 
fm244 3.21e+11 
E244 0.01 0.1 0.2 0.5 1 2 5 10 
c Photon RBE-Dose in tumor (rem/hr) 
f254:p 19 
fm254 3.21e+11 
de254 0.01 0.015 0.02 0.03 0.04 0.05 0.06 0.08 0.1 0.15 0.2 0.3 0.4 0.5 
     0.6 0.8 1 1.5 2 3 4 5 6 8 10 
df254 2.78e-6 1.11e-6 5.88e-7 2.56e-7 1.56e-7 1.2e-7 1.11e-7 1.2e-7 
     1.47e-7 2.38e-7 3.45e-7 5.56e-7 7.69e-7 9.09e-7 1.14e-6 1.47e-6 
     1.79e-6 2.44e-6 3.03e-6 4e-6 4.76e-6 5.56e-6 6.25e-6 7.69e-6 
9.09e-6 
c Neutron Fluence in tumor 
f264:n 19 
fm264 3.21e+11 
E264 0.0000005 0.000001 0.00001 0.0001 .001 .01 .1 1 10 
c RBE-Dose in tumor (rem/hr) 
f274:n 19 
fm274 3.21e+11 
de274 2.5e-8 1e-7 1e-6 1e-5 1e-4 1e-3 1e-2 1e-1 5e-1 1 2.5 5 7 10 
df274 3.67e-6 3.67e-6 4.46e-6 4.54e-6 4.18e-6 3.76e-6 3.56e-6 2.17e-5 
     9.26e-5 1.32e-4 1.25e-4 1.56e-4 1.47e-4 1.47e-4 
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c====================================================================== 
c                                 Tumor at 8 cm 
c====================================================================== 
c Photon Fluence in tumor 
f284:p 20 
fm284 3.21e+11 
E284 0.01 0.1 0.2 0.5 1 2 5 10 
c Photon RBE-Dose in tumor (rem/hr) 
f294:p 20 
fm294 3.21e+11 
de294 0.01 0.015 0.02 0.03 0.04 0.05 0.06 0.08 0.1 0.15 0.2 0.3 0.4 0.5 
     0.6 0.8 1 1.5 2 3 4 5 6 8 10 
df294 2.78e-6 1.11e-6 5.88e-7 2.56e-7 1.56e-7 1.2e-7 1.11e-7 1.2e-7 
     1.47e-7 2.38e-7 3.45e-7 5.56e-7 7.69e-7 9.09e-7 1.14e-6 1.47e-6 
     1.79e-6 2.44e-6 3.03e-6 4e-6 4.76e-6 5.56e-6 6.25e-6 7.69e-6 
9.09e-6 
c Neutron Fluence in tumor 
f304:n 20 
fm304 3.21e+11 
E304 0.0000005 0.000001 0.00001 0.0001 .001 .01 .1 1 10 
c RBE-Dose in tumor (rem/hr) 
f314:n 20 
fm314 3.21e+11 
de314 2.5e-8 1e-7 1e-6 1e-5 1e-4 1e-3 1e-2 1e-1 5e-1 1 2.5 5 7 10 
df314 3.67e-6 3.67e-6 4.46e-6 4.54e-6 4.18e-6 3.76e-6 3.56e-6 2.17e-5 
     9.26e-5 1.32e-4 1.25e-4 1.56e-4 1.47e-4 1.47e-4 
c====================================================================== 
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c                                Material Cards 
c====================================================================== 
M1 82207 1 $lead 
M3 13027.21c 1 $aluminum 
M5 6012.21c 1 $carbon 
M7 6012.21c -0.000124 7014.60c -0.755268 8016.60c -0.231781 18000.42c -
0.012827 $air 
M8 1001.60c -0.111898 8016.60c -0.888102 $target 
c M9 13027 -0.432 9019 -0.559 3007 -0.009 $aluminum/fluorine/lithium 
moderator 
M10 1002.60c -0.2 8016.60c -0.8 $d2o 
c M11 4009.60c 1 8016.60c 1 $BeO 
M12 24000.42c -0.12 26000.21c -0.8775 6012.21c -0.0025 $steel 
M13 1001.60c -0.107 6012.21c -0.145 7014.60c -0.022 8016.60c -0.712 
     11023.60c -0.002 15031.60c -0.004 16000.60c -0.002 17000.60c -
0.003 
     19000.60c -0.003 $brain 
CTME 10000 
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APPENDIX B 
MCNP INPUT FILE FOR THE PHOTON DOSE CALCULATION 
 
Isotropic source with 30 cm moderator (Fluental) thickness           
1 8 -1 -1 29 -10 imp:n,p=1 $water (target)                          
2 12 -7.85 -1 10 -11 imp:n,p=1 $steel cover                         
3 1 -11.34 -2 11 -12 imp:n,p=1 $lead shield                        
4 10 -1 13 -3 -16 -14 imp:n,p=1 $moderator heavy water              
5 3 -2.7 12 -4 -17 -15 #4 imp:n,p=1 $aluminum container            
6 5 -2.267 (5 -6 7 -8 12 -15 4):(5 -6 7 -8 -12 11 2):               
      (5 -6 7 -8 9 -11 1) imp:n,p=1 $graphite reflector             
7 1 -11.34 -4 17 -15 imp:n,p=1 $lead collimator                    
8 12 -7.85 5 -6 7 -8 18 -9 imp:n,p=1 $steel wall                    
9 13 -1.04 -20 #10 #14 #15 #16 #17 #18 #19 #20 imp:n,p=1 $phantom  
10 13 -1.04 -21 imp:n,p=1 $tumor at 1 cm                          
14 13 -1.04 -22 imp:n,p=1 $tumor at 2 cm                           
15 13 -1.04 -23 imp:n,p=1 $tumor at 3 cm                          
16 13 -1.04 -24 imp:n,p=1 $tumor at 4 cm                         
17 13 -1.04 -25 imp:n,p=1 $tumor at 5 cm                          
18 13 -1.04 -26 imp:n,p=1 $tumor at 6 cm                          
19 13 -1.04 -27 imp:n,p=1 $tumor at 7 cm                          
20 13 -1.04 -28 imp:n,p=1 $tumor at 8 cm                          
21 7 -0.001205 (-5:6:-7:8:-18:15) -19 #9 #10 #14 #15 #16          
      #17 #18 #19 #20 imp:n,p=1 $air                              
12 0 19 imp:n,p=0 $vacuum                                         
13 7 -0.001205 -1 9 -29 imp:n,p=1$ target air                     
1 cy 5                                                           
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2 cy 10                                                           
3 cy 15                                                         
4 cy 16                                                           
5 px -46                                                          
6 px 46                                                           
7 pz -46                                                          
8 pz 46                                                           
9 py -17                                                          
10 py 3                                                         
11 py 4                                                          
12 py 8                                                         
13 py 9                                                         
14 py 39                                                       
15 py 40                                                          
16 ky 60 0.3333333 -1                                             
17 ky 61 0.3333333 -1                                             
18 py -18                                                       
19 sy 10 100                                                     
20 SQ 0.010412328 0.021626297 0.014515894 0 0 0 -1 0 47 0        
21 sy 41.2 0.25                                                   
22 sy 42.2 0.25                                                   
23 sy 43.2 0.25                                                   
24 sy 44.2 0.25                                                   
25 sy 45.2 0.25                                                  
26 sy 46.2 0.25                                                   
27 sy 47.2 0.25                                                   
28 sy 48.2 0.25                                                   
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29 py 2                                                           
 
mode p 
VOL 8j 2306.889162 11j 
AREA 19j 862.075375 9j 
c====================================================================== 
c                            Isotropic Photon Source  
c====================================================================== 
sdef par=2 erg=d1 pos=0 2.5 0 
# si1 sp1 
0.001 0 
1 8.8e+11 
2 7.4e+11 
3 2.6e+11 
4 1.6e+11 
5 8.7e+10 
6 4.6e+10 
7 2.2e+10 
8 8.8e+9 
9 2e+9 
c====================================================================== 
c                                 Tumor at 1 cm 
c====================================================================== 
c Photon Fluence in tumor 
f4:p 10 
fm4 2.206e+12 
E4 0.01 0.1 0.2 0.5 1 2 5 10 
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c Photon RBE-Dose in tumor (rem/hr) 
f14:p 10 
fm14 2.206e+12 
de14 0.01 0.015 0.02 0.03 0.04 0.05 0.06 0.08 0.1 0.15 0.2 0.3 0.4 0.5 
     0.6 0.8 1 1.5 2 3 4 5 6 8 10 
df14 2.78e-6 1.11e-6 5.88e-7 2.56e-7 1.56e-7 1.2e-7 1.11e-7 1.2e-7 
     1.47e-7 2.38e-7 3.45e-7 5.56e-7 7.69e-7 9.09e-7 1.14e-6 1.47e-6 
     1.79e-6 2.44e-6 3.03e-6 4e-6 4.76e-6 5.56e-6 6.25e-6 7.69e-6 
9.09e-6 
c====================================================================== 
c                                 Tumor at 2 cm 
c====================================================================== 
c Photon Fluence in tumor 
f44:p 14 
fm44 2.206e+12 
E44 0.01 0.1 0.2 0.5 1 2 5 10 
c Photon RBE-Dose in tumor (rem/hr) 
f54:p 14 
fm54 2.206e+12 
de54 0.01 0.015 0.02 0.03 0.04 0.05 0.06 0.08 0.1 0.15 0.2 0.3 0.4 0.5 
     0.6 0.8 1 1.5 2 3 4 5 6 8 10 
df54 2.78e-6 1.11e-6 5.88e-7 2.56e-7 1.56e-7 1.2e-7 1.11e-7 1.2e-7 
     1.47e-7 2.38e-7 3.45e-7 5.56e-7 7.69e-7 9.09e-7 1.14e-6 1.47e-6 
     1.79e-6 2.44e-6 3.03e-6 4e-6 4.76e-6 5.56e-6 6.25e-6 7.69e-6 
9.09e-6 
c====================================================================== 
c                                 Tumor at 3 cm 
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c====================================================================== 
c Photon Fluence in tumor 
f84:p 15 
fm84 2.206e+12 
E84 0.01 0.1 0.2 0.5 1 2 5 10 
c Photon RBE-Dose in tumor (rem/hr) 
f94:p 15 
fm94 2.206e+12 
de94 0.01 0.015 0.02 0.03 0.04 0.05 0.06 0.08 0.1 0.15 0.2 0.3 0.4 0.5 
     0.6 0.8 1 1.5 2 3 4 5 6 8 10 
df94 2.78e-6 1.11e-6 5.88e-7 2.56e-7 1.56e-7 1.2e-7 1.11e-7 1.2e-7 
     1.47e-7 2.38e-7 3.45e-7 5.56e-7 7.69e-7 9.09e-7 1.14e-6 1.47e-6 
     1.79e-6 2.44e-6 3.03e-6 4e-6 4.76e-6 5.56e-6 6.25e-6 7.69e-6 
9.09e-6 
c====================================================================== 
c                                 Tumor at 4 cm 
c====================================================================== 
c Photon Fluence in tumor 
f124:p 16 
fm124 2.206e+12 
E124 0.01 0.1 0.2 0.5 1 2 5 10 
c Photon RBE-Dose in tumor (rem/hr) 
f134:p 16 
fm134 2.206e+12 
de134 0.01 0.015 0.02 0.03 0.04 0.05 0.06 0.08 0.1 0.15 0.2 0.3 0.4 0.5 
     0.6 0.8 1 1.5 2 3 4 5 6 8 10 
df134 2.78e-6 1.11e-6 5.88e-7 2.56e-7 1.56e-7 1.2e-7 1.11e-7 1.2e-7 
 
 112
     1.47e-7 2.38e-7 3.45e-7 5.56e-7 7.69e-7 9.09e-7 1.14e-6 1.47e-6 
     1.79e-6 2.44e-6 3.03e-6 4e-6 4.76e-6 5.56e-6 6.25e-6 7.69e-6 
9.09e-6 
c====================================================================== 
c                                 Tumor at 5 cm 
c====================================================================== 
c Photon Fluence in tumor 
f164:p 17 
fm164 2.206e+12 
E164 0.01 0.1 0.2 0.5 1 2 5 10 
c Photon RBE-Dose in tumor (rem/hr) 
f174:p 17 
fm174 2.206e+12 
de174 0.01 0.015 0.02 0.03 0.04 0.05 0.06 0.08 0.1 0.15 0.2 0.3 0.4 0.5 
     0.6 0.8 1 1.5 2 3 4 5 6 8 10 
df174 2.78e-6 1.11e-6 5.88e-7 2.56e-7 1.56e-7 1.2e-7 1.11e-7 1.2e-7 
     1.47e-7 2.38e-7 3.45e-7 5.56e-7 7.69e-7 9.09e-7 1.14e-6 1.47e-6 
     1.79e-6 2.44e-6 3.03e-6 4e-6 4.76e-6 5.56e-6 6.25e-6 7.69e-6 
9.09e-6 
c====================================================================== 
c                                 Tumor at 6 cm 
c====================================================================== 
c Photon Fluence in tumor 
f204:p 18 
fm204 2.206e+12 
E204 0.01 0.1 0.2 0.5 1 2 5 10 
c Photon RBE-Dose in tumor (rem/hr) 
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f214:p 18 
fm214 2.206e+12 
de214 0.01 0.015 0.02 0.03 0.04 0.05 0.06 0.08 0.1 0.15 0.2 0.3 0.4 0.5 
     0.6 0.8 1 1.5 2 3 4 5 6 8 10 
df214 2.78e-6 1.11e-6 5.88e-7 2.56e-7 1.56e-7 1.2e-7 1.11e-7 1.2e-7 
     1.47e-7 2.38e-7 3.45e-7 5.56e-7 7.69e-7 9.09e-7 1.14e-6 1.47e-6 
     1.79e-6 2.44e-6 3.03e-6 4e-6 4.76e-6 5.56e-6 6.25e-6 7.69e-6 
9.09e-6 
c====================================================================== 
c                                 Tumor at 7 cm 
c====================================================================== 
c Photon Fluence in tumor 
f244:p 19 
fm244 2.206e+12 
E244 0.01 0.1 0.2 0.5 1 2 5 10 
c Photon RBE-Dose in tumor (rem/hr) 
f254:p 19 
fm254 2.206e+12 
de254 0.01 0.015 0.02 0.03 0.04 0.05 0.06 0.08 0.1 0.15 0.2 0.3 0.4 0.5 
     0.6 0.8 1 1.5 2 3 4 5 6 8 10 
df254 2.78e-6 1.11e-6 5.88e-7 2.56e-7 1.56e-7 1.2e-7 1.11e-7 1.2e-7 
     1.47e-7 2.38e-7 3.45e-7 5.56e-7 7.69e-7 9.09e-7 1.14e-6 1.47e-6 
     1.79e-6 2.44e-6 3.03e-6 4e-6 4.76e-6 5.56e-6 6.25e-6 7.69e-6 
9.09e-6 
c====================================================================== 
c                                 Tumor at 8 cm 
c====================================================================== 
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c Photon Fluence in tumor 
f284:p 20 
fm284 2.206e+12 
E284 0.01 0.1 0.2 0.5 1 2 5 10 
c Photon RBE-Dose in tumor (rem/hr) 
f294:p 20 
fm294 2.206e+12 
de294 0.01 0.015 0.02 0.03 0.04 0.05 0.06 0.08 0.1 0.15 0.2 0.3 0.4 0.5 
     0.6 0.8 1 1.5 2 3 4 5 6 8 10 
df294 2.78e-6 1.11e-6 5.88e-7 2.56e-7 1.56e-7 1.2e-7 1.11e-7 1.2e-7 
     1.47e-7 2.38e-7 3.45e-7 5.56e-7 7.69e-7 9.09e-7 1.14e-6 1.47e-6 
     1.79e-6 2.44e-6 3.03e-6 4e-6 4.76e-6 5.56e-6 6.25e-6 7.69e-6 
9.09e-6 
c====================================================================== 
c                                Material Cards 
c====================================================================== 
M1 82000 1 $lead 
M3 13000 1 $aluminum 
M5 6000 1 $carbon 
M7 6000 -0.000124 7000 -0.755268 8000 -0.231781 18000 -0.012827 $air 
M8 1000 -0.111898 8000 -0.888102 $target 
c M9 13027 -0.432 9019 -0.559 3007 -0.009 $aluminum/fluorine/lithium 
moderator 
M10 1000 -0.2 8000 -0.8 $d2o 
c M11 4000 1 8000 1 $BeO 
M12 24000 -0.12 26000 -0.8775 6012 -0.0025 $steel 
M13 1000 -0.107 6000 -0.145 7000 -0.022 8000 -0.712 
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     11000 -0.002 15000 -0.004 16000 -0.002 17000 -0.003 
     19000 -0.003 $brain 
CTME 10000 
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